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ABSTRACT 
 
   Mutations in copper (Cu) transporter ATP7B are the primary cause of 
Wilson Disease (WD). WD is an autosomal recessive disorder 
characterized by hepatic cirrhosis and neuronal degeneration due to a 
severe impairment in biliary Cu excretion. The defective gene in WD 
encodes ATP7B, a Cu-trasporting protein primarily expressed in the liver. 
Generally, ATP7B senses and responds to intracellular Cu levels via 
trafficking from the trans-Golgi network (TGN) toward post late-endosome 
(LE)/lysosomal compartments and plasma membrane (PM) to eliminate 
excessive Cu from the cell via bile canaliculi. The most frequent ATP7B 
disease-associated mutation (H1069Q) results in aberrant protein products 
that are mis-targeted from the Golgi complex to the endoplasmic reticulum 
(ER). However, ATP7B-H1069Q mantains a residual Cu-translocating 
activity believed to be sufficient to rescue Cu homeostasis when the protein 
is targeted to TGN (Kaler SG. et al., 2011). 
My research project expands previous studies conducted in my laboratory   
showing that the cytosolic holdase αB-Crystallin (CryAB or Hsp-B5) 
rescues the localization and trafficking response of ATP7B-H1069Q  to Cu 
overload (D’Agostino M. et al., 2013). 
In brief, the project was divided into two lines of research performed in 
collaboration with another Ph.D student Simona Allocca. 
In the first line of research, we studied the effects of phosphorylation on 
CryAB full length structure and function and how phosphorylation can 
influence CryAB chaperone activity on ATP7B mutant. Our results show 
that mimicking phosphorylation of serine 19 and 45, either singularly or in 
combination reduces CryAB chaperone function. By contrast, 
phosphorylation of serine 59 has no such effect and counteracts the 
inhibition caused by single phosphorylation at S19 and S45. In addition, 
we found that all phosphomimetic substitutions lead to the formation of 
small oligomeric complexes containing CryAB, thereby suggesting that the 
reduction of the oligomerization state of CryAB does not correlate with the 
inhibition of its chaperone activity (Ciano M. et al., 2016). 
In the second line of research, we verified the rescue ability of CryAB 
domains on ATP7B-H1069Q. To this aim, we dissected CryAB in its main 
domains: N-terminal, α-crystallin, and C-terminal. Subsequently, we 
assayed them through immunofluorescence analysis in cells co-transfected 
with ATP7B-H1069Q. We found that the α-crystallin domain is able to 
rescue the Golgi localization of the ATP7B-H1069Q mutant. Then, since 
several studies have shown that small CryAB derived peptides are able to 
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mimic the effect of the full length protein, (Sreekumar P.G. et al., 2013; 
Nahomi R.B. et al., 2015), we focused on peptide 73-92, derived from the 
crystallin-domain of CryAB (Peptide1 or Pept1) in our WD cellular model. 
Our results revealed that Peptide1 retains the ability to rescue the Golgi 
localization of ATP7B-H1069Q, thereby fully mimicking the effects of the 
isolated α-crystallin domain and full-length CryAB. Furthermore, we 
observed that Peptide1 and Control Peptide (Ctrl Pept) are taken up by 
COS7 and do not affect cell viability. Interestingly, we also demonstrated 
that Pept1, but not Ctrl Pept, is able not only to interact with ATP7B WT 
and H1069Q, but also to correct the localization of ATP7B-H1069Q from 
the ER to the TGN and to the post-TGN trafficking in response to toxic Cu. 
Moreover, our experiments revealed that Pept1 is also able to stabilize 
ATP7B-H1069Q, thereby increasing its half-life. 
Finally, in collaboration with Dr. Silvia Parisi, Anna Musto, Simona 
Allocca, and Prof. Roman Polishchuk, we generated an isogenic cell model 
from iPSCs obtained from skin fibroblasts of a WD patient carrying the 
H1069Q mutation (H1069Q/H1069Q) and a familiar control 
(WT/H1069Q), and differentiated them into hepatocyte-like cells HLCs. 
Therefore, our future objective is to exploit these cells to study the 
expression, localization, mobilization, and function of the mutant ATP7B-
H1069Q, and to test the rescue efficiency of peptide CryAB 73-92 
(Peptide1). 
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Abbreviations: 
 
AAT, α1-antitrypsin;  
ACD, α-crystallin domain; 
AFP, αfetoprotein;  
ALB, albumin;  
Chx, Cycloheximide;  
CP, ceruloplasmin; 
CryAB or HSPB5, αB-crystallin;  
CTE, C-terminal extension; 
CTR1, copper transporter 1;  
Ctrl Pept, control peptide;  
Cu, copper;  
ER, endoplasmic reticulum;  
ERK, p44/42 MAPK, p44/42 mitogen-activated protein kinase; 
FLIM, Fluorescence-lifetime imaging microscopy;  
HLCs, Hepatocyte-like cells;  
HSPs, Heat Shock Proteins;  
iPSCs, induced pluripotent stem cells;  
MBDs, metal binding domains; 
MD, Menkes Disease;  
MTT, 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide;  
N-terminal domain, NTD; 
p38, MAPK14, mitogen-activated protein kinase 14;  
Pept1, αB-crystallin-derived peptide or peptide1; 
Pept2, control peptide or peptide2;  
Pept3, control peptide or peptide3; 
PM, Plasma Membrane;  
sHSPs, small Heat Shock Proteins;  
TAMRA, Tetramethylrhodamine;  
TGN, Trans Golgi Network; 
TMP, multispan transmembrane protein;  
UPR, unfolded protein response; 
WD, Wilson Disease. 
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1.   INTRODUCTION 
 
 
1.1 Copper homeostasis 
 
   Copper (Cu) is an essential micronutrient that plays a fundamental role 
in human metabolism. It is an important cofactor for many proteins and 
enzymes including superoxide dismutase 1 (Cu/Zn-SOD), cytochrome c 
oxidase (COX), lysyl oxidase, tyrosinase, dopamine-β-hydroxylase, and 
ceruloplasmin (CP) (Arredondo M. and Núñez MT. 2005; de Bie P. et al., 
2007), which are involved in respiration, free radical scavenging, 
pigmentation, iron metabolism, collagen synthesis, elastin, and 
neurotrasmettitors.  
For proper cellular function, the body needs to uptake an average of 1-3 mg 
of Cu daily. (Lutsenko S. et al., 2007; Lutsenko S. et al., 2010; Nevitt T. et 
al., 2012). Indeed, when concentrations exceed the body’s needs, Cu 
induces cellular toxicity because of its chemical redox potential. 
Accordingly, the amount of Cu in the body is carefully regulated. The main 
biochemical regulators of cellular copper metabolism are the Cu-
transporting ATPases (Cu-ATPases) ATP7A and ATP7B. Mutations in 
ATP7A or ATP7B are associated with severe metabolic disorders, as they 
disrupt Cu homeostasis. In particular, disturbances in ATP7A result in Cu 
deficiency (Menkes disease, MD), whereas those in ATP7B give rise to Cu 
overload (Wilson disease, WD) (de Bie et al., 2007). 
Most of Cu absorption takes place in the duodenum. In brief, dietary Cu is 
taken up by enterocytes and is then delivered to the liver through the portal 
vein. This step is however blocked in MD (blue bars in Fig 1). After 
entering hepatocytes, Cu is distributed to other tissues through the general 
circulation. The great majority of Cu excretion from the body (98%) is 
performed by biliary export, suggesting that the liver consitutes the central 
organ of Cu homeostasis. In WD, Cu excretion from the liver is defective 
(red bars in Fig. 1), causing excess Cu overload in the liver (de Bie P. et 
al., 2007). Under physiological conditions, Cu uptake in cells occurs 
through the Cu transporter 1 (CTR1) and is subsequently distributed by the 
Cu chaperone ATOX1 to ATP7A or ATP7B, residing in the trans-Golgi 
network (TGN) of enterocytes and hepatocytes, respectively. Increased 
levels of Cu prompt ATP7A and ATP7B to move from the TGN to the 
plasma membrane (PM) to facilitate Cu excretion. Therefore, ATP7A and 
ATP7B play a crucial role in excreting Cu from cells (de Bie P. et al., 
2007). 
                                                                                                              1. Introduction 
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Figure 1. Schematic representation of Cu homeostasis (de Bie P. et al., 2007). 
 
 
 
 
Figure 2. Schematic illustration of Cu-dependent localization of ATP7A and ATP7B. 
In both cell, enterocyte (left side) and hepatocyte (right side), Cu enters through the Cu 
transporter 1 (CTR1), and is then distributed via the Cu chaperone ATOX1 to ATP7A or 
ATP7B residing in the TGN. After increases in Cu concentrations, ATP7A and ATP7B 
relocalize from the TGN to the cell periphery to facilitate Cu excretion (de Bie P. et al., 
2007). 
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1.2 Copper-transporting ATPases ATP7A and ATP7B in human diseases 
 
   Cu-ATPases are essential for maintaining Cu balance in cells and 
tissues. These evolutionary conserved polytopic membrane proteins 
translocate Cu from the cytosol across cellular membranes by using ATP 
hydrolysis energy, thus reducing intracellular Cu concentrations. In 
addition to removing excess Cu from the cell, Cu-ATPases perform 
important biosynthetic functions by supplying Cu to Cu-dependent 
enzymes within the secretory pathway. The importance of Cu-ATPases in 
human physiology can be illustrated by inherited copper-transport diseases 
resulting from mutations in the genes encoding ATP7A and ATP7B (De 
Bie P. et al., 2007; Lutsenko S. et al., 2007). 
Mutations in the gene encoding the Cu-ATPase ATP7A cause Menkes 
disease (MD), a fatal X-linked copper-deficiency disorder in infants. Under 
physiological conditions, ATP7A facilitates Cu export from the enterocytes 
into the blood at the basolateral side. In MD, ATP7A is inactivated, thereby 
severely impairing the cell’s ability to excrete Cu into the bloodstream. As 
a result, the more Cu accumulates in intestinal epithelium cells, the less it 
is delivered to the bloodstream, resulting in restricted Cu supply to other 
tissues (Kodama H. et al., 1999). Copper deficiency is characterized by 
neurodegeneration, growth failure, coarse hair, and connective tissue 
abnormalities (Kaler S.G. et al., 2011). On the other hand, mutations in the 
gene encoding the Cu-ATPase ATP7B lead to Wilson disease (WD), an 
autosomal recessive genetic disorder. Unlike MD, this disease is caused by 
toxic accumulation of Cu mainly in the liver and brain with development 
of severe hepatic, neurological, and psychiatric symptoms (see below) 
(Lutsenko S. et al., 2007). 
 
 
1.3 Wilson Disease (WD) 
 
   WD, an autosomal recessive inherited disorder of Cu metabolism, is 
characterized by pathological Cu accumulation predominantly in liver and 
brain, where it induces cellular damage. However, it can also affect other 
organ systems like the kidneys, cornea, heart, and pancreas.  
WD is observed with a prevalence of approximately 1:30,000 with a 
heterozyogous ATP7B mutation carrier frequency of 1:90. Although the 
usual age of onset ranges from 3 to 50 years of age, this disorder has been 
detected in children as young as 3 and in adults as old as 70 (Ferenci P. 
2003). 
                                                                                                              1. Introduction 
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This disorder is produced by mutational defects of a protein that facilitates 
hepatic Cu excretion. The defective gene in WD encodes ATP7B 
(chromosome 13q14.3), a Cu-transporting protein primarily expressed in 
the liver (van de Berghe PV et al., 2009). 
 
This disease may present a variety of clinical conditions: commonly, 
hepatic and/or neuropsychiatric disorders; rarely, renal, skeletal, 
or endocrine symptomatology. In particular, approximately 45% of all WD 
patients present with liver disease, 35% with neurological defects, and 10% 
with psychiatric disturbances. The remaining 10% of initial presentations 
include hemolytic anemia, cardiomyopathy, jaundice, and a number of 
other less common conditions, all of which resulting from copper-mediated 
tissue injury. The great majority of patients (90%) present with Kayser-
Fleischer rings, a deposition of copper in Descemet’s membrane visible as 
a gold–brown ring around the outer edge of the cornea (Fig. 3) (Roberts 
E.A. and Schilsky M.L. 2003; Gitlin J.D. 2003; Ferenci P. 2003; de bie P. 
et al., 2007). 
The diagnosis of WD is very challenging, as it is based on a combination 
of symptoms and on the results of clinical, biochemical, and genetic tests. 
The tests used to diagnose WD include the following:  
•   Biochemical liver tests: Serum aminotransferase activities are 
generally increased in WD patients. 
•   24-hours urine Cu test: Basal 24-hours urinary copper excretion is 
commonly elevated in WD. 
•   Serum Cu: Total serum Cu is usually decreased in proportion to the 
reduced ceruloplasmin levels in the circulation. However, in acute 
liver failure, it may be elevated because of the sudden release of Cu 
from liver tissue damage. 
•   Serum ceruloplasmin test: The serum ceruloplasmin is usually 
decreased in WD patients. 
•   Opthalmalogic slit lamp examination for Kayser-Fleischer (KF) 
rings. 
•   Liver biopsy for histology and histochemistry and Cu 
quantification. 
•   Neuroimaging: MRIs of the brain or CAT scans may detect 
structural abnormalities. 
•   Genetic testing for ATP7B mutations: A blood test identifies the 
genetic mutations that cause Wilson disease (Fig. 4) (Roberts E.A. 
and Schilsky M.L. 2003). 
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It is important to diagnose WD as early as possible since severe liver 
damage can occur before any signs of the disease begin to appear. 
Fortunately, if diagnosed and treated early enough, WD patients can live 
longer lives and enjoy a good quality of life. 
 
Wilson disease treatment is based on two different approaches: (1) 
prompting Cu excretion from the body, (2) reducing dietary Cu absorption. 
The first approach is achieved by Cu chelation agents like D-penicillamine, 
trientine, or ammonium tetrathiomolybdate (TTM). Pharmacodynamically 
speaking,  D-penicillamine binds Cu and enables patients to excrete excess 
Cu accumulated in the liver through their urine. Similarly, trientine gives 
the same results as D-penicillamine, but with fewer side effects, which 
commonly include hypersensitivity reactions, bone marrow suppression, 
and autoimmune diseases.  
The second approach is obtained by ingestion of zinc and a low Cu diet. 
More recently, experimental treatments with TTM have revealed promising 
results particularly because when taken with meals, it prevents dietary Cu 
absorption. Furthermore, TTM appears to be an excellent form of initial 
treatment in patients who have neurological symptoms. Dietary Cu 
absorption is effectively inhibited by zinc ingestion and by low Cu diet. 
Accordingly, physcians recommend avoiding certain types of foods 
including mushrooms, nuts, chocolate, dried fruits, liver and molluscs. In 
effect, zinc interferes with the uptake of Cu from the gastrointestinal tract, 
by inducing metallothionein production in enterocytes, a cysteine-rich 
protein that is an endogenous chelator of metals. Having a greater affinity 
for Cu than for zinc, it inhibits Cu entry into the portal circulation. 
Ultimately, once bound, Cu is no longer absorbed but is lost in the feces 
(Roberts E.A. and Schilsky M.L, 2008). 
Today, the mainstay of treatment for WD remains lifelong zinc-based 
pharmacological therapy; however, if treatment is ineffective, or in 
circumstances of fulminant liver failure, liver transplantation provides an 
effective cure (Fig. 5) (Roberts E.A and Schilsky M.L 2003; de Bie P. et 
al., 2007). 
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Figure 3. Clinical Patterns of Hepatic, Neurological, and Psychiatric Disorders in 
WD patients (Roberts E.A and Schilsky M.L 2003). 
 
 
 
 
Figure 4. Schematic illustration of the diagnostic criteria for WD. 
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Figure 5. Pharmacological Treatment Modalities for WD (Roberts E.A and Schilsky 
M.L 2003). 
 
 
1.4 Pathophysiology of the ATPase transporter ATP7B  
 
   ATP7B, the Cu-ATPase transporter involved in WD, is a multispan 
transmembrane protein (TMP) composed of 1465 amino acids. It contains 
eight transmembrane helices, which form a channel that pumps Cu from 
the cytosol at the expense of ATP hydrolysis (Fig. 6). 
The NH2-terminal portion of ATP7B is large (600 residues) and is 
composed of six metal binding domains (MBDs) that are connected by 
flexible loops. Each MBD binds one Cu and contains the repetitive 
sequence motif MxCxxC. Cu binds in the reduced Cu(I) form, and the two 
Cys residues in the metal-binding motif CxxC are the only Cu-coordinating 
ligands (Di Donato M. et al., 2000; Wu F. et al., 2015; Lutsenko S. et al., 
2007). In vitro, and perhaps in vivo, other metals such as zinc (Di Donato 
M. et al., 2002) or lead (Qian Y. et al., 2005) also bind to the NH2-terminal 
domain; however, the functional consequences and physiological 
significance of zinc or lead binding still remain unknown. The MxCxxC 
motifs are the site of Atox1 interaction and subsequent Cu binding (Wu F. 
et al., 2015). Recent studies demonstrate that although mutation of all six 
NH2-terminal MBDs in ATP7B does not alter protein expression, it does 
disrupt ATP7B function (Cater M.A. et al., 2004). The conserved Met, Leu, 
and Phe (Pro in MBD3) residues, spatially close to the CxxC motif, form a 
hydrophobic nucleus that probably establishes the metallic protein complex 
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(Lutsenko S. et al., 2007). 
The catalytic activity of ATP7B (the binding and hydrolysis of ATP) is 
mediated through the coordinated action of the A-domain and the ATP-
binding domain. The latter consists of two domains: the phosphorylation 
domain (the P-domain) and the nucleotide-binding domain (the N-domain) 
(Efremov R.G. et al., 2004).  
The P-domain contains the highly conserved sequence motif DKTG, which 
is essential for enzyme phosphorylation. In turn, phosphorylation of 
aspartic acid residue (Asp) from the DKTG sequence is crucial for Cu 
transport. Acyl-phosphates are in effect the phosphorylated intermediates 
that determine protein conformational changes and Cu transport to the 
opposite side of the membrane (Miller J.V. et al., 1996).  
The N-domain is instead involved in nucleotide binding (ATP) and 
contributes to ATP coordination. This domain contains a highly conserved 
SEHPL sequence. The histidine residue in this motif is conserved in all 
known Cu-transporting ATPases and is the site of the most common 
mutation (H1069Q) in WD patients (Thomas G. R et al., 1995). 
The A-domain is the place where acyl-phosphates are dephosphorylated. 
This domain contains a Thr–Gly–Glu sequence motif (TGE) in which the 
Glu residue is crucial for phosphatase activity. Dephosphorylation of acyl-
phosphates marks the completion of the cycle (Petris M.J. et al., 2002).  
The cytosolic C-terminal domain is relatively short (80–100 residues) and 
contains conserved trileucine motifs, which are required for retrieval of the 
transporter from the PM and vesicles (Mercer J.F. et al., 2003; Petris M.J. 
et al., 1998). Therefore, the C-terminal plays an important role in 
maintaining protein stability and in regulating protein location (Fig. 6) (Hsi 
G. et al., 2004). 
As for its function, ATP7B, which is localized in the TGN, receives dietary 
Cu from the cytosolic metallochaperone, Atox1. ATP7B then transfers Cu 
across the membrane into the lumen of the TGN. In hepatocytes, following 
transport into the lumen, Cu is incorporated into the Cu-dependent 
ferroxidase ceruloplasmin (CP), which is subsequently secreted into the 
blood. Excess cytosolic Cu induces ATP7B to move from the TGN to the 
endo-lysosomal organelles and to the PM of bile canaliculi to guarantee Cu 
excretion through the bile (Fig. 7) (Wu F. et al., 2015). 
More than 200 mutations WD gene have been reported to hamper the 
function of ATP7B. Mutations affect every position of the gene, including 
exons, introns and promoters. They have been classified as frameshift, 
nonsense, involved in splicing defects and missense mutations. The latter 
are the most common and are associated with a more severe WD phenotype 
(Gromadzka G. et al., 2005) In particular, the most common missense 
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mututations are H1069Q (in Europe) and R778L (in Asia) (Ferenci P. 
2004). 
ATP7B-H1069Q is the most frequent WD-causing mutation among the 
Caucasian population (50%), where the histidine in position 1069 is 
substituted with a glutamine (de Bie P. et al., 2007; Lutsenko S. et al., 2007; 
Payne A.S. et al., 1998). The mutation alters the structure of NBD 
(Dmitriev O.Y. et al., 2011). In brief, the protein becomes thermally 
unstable and can no longer pass the quality control, thereby accumulating 
in the ER of hepatocytes. Consequently ATP7B-H1069Q, unlike wild-type 
ATP7B, fails to reach the Golgi complex and to move further towards 
LE/lysosomal compartments and the PM in response to Cu overload. 
Moreover, the H1069Q mutant has a decreased half-life compared with the 
wild-type ATP7B (Dmitriev O.Y. et al., 2011) and is thus rapidly degraded. 
Recently, studies have shown that expression of this ATP7B mutant 
activates the p38 and JNK stress kinase pathways, which, in turn, lead to 
the enhanced arrest and degradation of the ATP7B-H1069Q in the ER. 
(Concilli M. et al., 2016). Therefore, failure to pump excess Cu out of 
hepatocytes into the bile duct causes the toxic buildup of Cu in the liver of 
WD patients (Fig. 8) (de Bie P. et al., 2007).  
Although little is known regarding ATP7B oligomerization, studies show 
that the 3rd and 4th Cu-binding sites in the N-terminal domain of ATP7B 
can aggregate in vitro (Banci L. et al., 2008). The hypothesis is that 
H1069Q mutation may weaken the interaction between the NBD and the 
N-terminal domain since several copies of the ATP7B mutant bind to each 
other through the 3rd and 4th Cu-binding sites in their N-terminal domains, 
thereby generating ATP7B-H1069Q aggregates. Intriguingly, although this 
mutation affects the NBD of the protein, it leaves a significant level of 
residual Cu transport activity ranging from 20 to 70% of wild-type ATP7B 
protein (van den Berghe V. E.  et al., 2009; Iida M. et al., 1998; Huster D. 
et al., 2012; Chandhok G. et al., 2016).	  Noteworthy, even just a residual 
Cu-translocating activity is believed to be sufficient for the rescue of Cu 
homeostasis if an ATPase mutant can be targeted to the proper destination 
(Kaler SG. 2011). Therefore, correction of the trafficking and localization 
of ATP7B-H1069Q should allow a substantial recovery of normal Cu 
metabolism, benefitting the majority of WD patients. Most important 
different treatments such as incubation at low temperature (Payne AS. et 
al., 1998) or with curcumine (van den Berghe V. E.  et al., 2009), or 
expression of CryAB (D’Agostino M. et al., 2013), or inhibition of p38 and 
JNK kinase (Chesi G. et al., 2016) have proven effective in rescuing 
localization and Cu response of the mutant. These findings show that once 
ATP7B-H1069Q moves beyond ER, it traffics similarly to wild type 
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ATP7B, thus suggesting interesting and promising new strategies to fight 
the disease (D'Agostino M. et al., 2013; Chesi G. et al., 2016). 
 
 
Figure 6. Schematic structure of ATP7B. ATP7B contains five regions: 1) an N-
terminal tail with six metal-binding sites, 2) eight trans-membrane segments (TMS), 3) an 
ATP-binding domain that contains a nucleotide-binding motif (N-domain, SEHPL), and a 
phosphorylation motif (P-domain, DKTGT), 4), an A domain (TGE motif), and 5) a C-
terminal tail. The H1069Q mutation occurs in the N domain (Wu F. et al., 2015). 
 
 
Figure 7. Schematic illustration of Cu transport and metabolism in the liver. Cu is 
delivered by the high-affinity Cu transport protein HCTR1 to the cytosol where it mainly 
binds to the metallochaperone, Atox1, which in turn transfers Cu to ATP7B located in the 
TGN. In the lumen of TGN, Cu is incorporated mostly into ceruloplasmin, which is 
released into the blood. Cu excess induces ATP7B to move from TGN to cytosolic vesicles 
to excrete Cu into the bile duct (De Bie P. et al., 2007). 
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Figure 8. Intracellular trafficking of ATP7B and ATP7B-H1069Q in the presence of 
low or high Cu concentration. Under normal Cu levels, ATP7B resides into the TGN. In 
response to copper overload, ATP7B moves to the cytosolic vesicles and to the PM to 
excrete excess Cu into the bile canaliculi. ATP7B-H1069Q does not reach the Golgi, 
remaining mainly into ER as misfolded aggregates. 
 
 
1.5 Small heat shock proteins 
   Unlike large heat shock proteins (HSPs) like HSP70 or HSP90, small heat 
shock proteins (sHSPs), hereafter called chaperones, are essential ‘holdase’ 
chaperones and cannot refold proteins (Narberhaus F. 2002). However, 
they sequester aberrant proteins to prevent subsequent formation of 
aggregates through an ATP-independent holdase activity. Subsequently, 
bound proteins can be transferred to ATP-dependent chaperones, such as 
Hsp70. Thanks to Hsp70, refolded and irreversibly damaged proteins are 
targeted to the ubiquitin-proteasome system (UPS) for degradation 
(Haslbeck M. and Buchner J. 2002). 
sHSPs form large oligomers comprising up to 50 subunits and respond to 
stress conditions (pH, temperature, reduction and oxidation) to protect 
target proteins from aggregation and precipitation. They are ubiquitous 
intracellular proteins characterized by a highly conserved crystallin-core 
domain containing 80-100 amino acid residues (Nahomi R.B.  et al., 2015). 
The human genome encodes 10 members of the sHSP family with a 
molecular mass in the range of 12-43 KDa (Rajagopal P. et al., 2015; 
                                                                                                              1. Introduction 
 
   15  
Arrigo A.P. et al., 2007). The major members of the sHsp family are Hsp20 
(HspB6), Hsp27 (HspB1) and αB-crystallin (Schwarz L. et al., 2009). 
Intriguingly, some sHsps show anti-apoptotic or anti-inflammatory effects 
and interact with cytoskeletal elements. In addition, these proteins are 
tumorigenic when expressed in cancer cells (Bartelt-Kirbach B. and 
Golenhofen N. 2013). 
Therefore, sHSPs are also involved in physio-pathological conditions and 
human diseases such as neurodegenerative disorders, myopathies, asthma, 
cataracts and cancers (Arrigo AP. et al., 2007). 
 
 
1.6 αB-Crystallin (CryAB or HSPB5) 
 
   Crystallin proteins are the major components of the mammalian lens fiber 
cell. They are subdivided into three classes, α, β, and γ, which account for 
nearly 90% of the lens proteins. α-Crystallin, a member of the sHSP family, 
is the predominant type (Bloemendal H. 1981). It exists as a large 
heterogeneous aggregate (~800 kDa) comprising two types of subunits, αA 
(HspB4) and αB (HspB5), in a 3:1 ratio in vivo with chaperone-like holdase 
function. Amino acid sequences of the two subunits share 55% homology 
with each other and with other sHSPs.  
In particular, αA-Crystallin is predominantly present in the lens, whereas 
αB-crystallin    in addition to being localized in the lens    is also present in 
several other tissues, including the retina, skeletal muscles, heart, and 
kidney (Nahomi RB. et al., 2013; Nagaraj RH. et al., 2015). The other two 
crystallins, β- and γ-crystallin, have no chaperone activity and serve as 
structural proteins (Bloemendal H. et al., 2004).  
Besides its chaperone activity, αB-Crystallin partecipates in many cellular 
functions. It inhibits several processes like protein aggregation, oxidative 
stress, apoptosis, and inflammation; moreover, it  provides neuroprotection 
and promotes angiogenesis, apoptosis, proteosomal protein degradation, 
and autophagy (Fig. 9) (Kannan R. et al., 2012). Regarding its angiogenetic 
properties, studies show that it directly acts as a chaperone for VEGF and 
other growth factors such as fibroblast growth factor-2 (FGF-2) (Ghosh JC. 
et al., 2007a).  
As for its anti-apoptotic properties, several findings have revealed that, in 
different cell types, αB-crystallin inhibits apoptosis in conditions of cellular 
stress induced by TNFα, UV light, high glucose, okadaic acid, and 
staurosporine. It inhibits apoptosis in both mitochondrial and death 
receptor-mediated pathways. Interestingly, several other studies have 
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shown that αB-crystallin directly interacts with pro-apoptotic Bcl-2-related 
proteins and Caspase-3, thereby preventing Bax and Bcl-XS mitochondrial 
translocation and caspase activation. Further, the antiapoptotic function of 
αB-crystallin is also due to activation of phosphatidylinositol-3-kinase (PI-
3K), and inhibition of phosphatase and tensin homolog (PTEN).   
In association with its anti-apoptotic properties, αB-crystallin protects 
various cell types during oxidative stress by increasing the expression of 
antioxidants, such as glutathione. Furthermore, in response to TNF-α 
treatment, αB-crystallin enhances phosphorylation and subsequent 
proteosomal degradation of IκBα, a crucial step in NF-κB activation 
(Adhikari AS. et al., 2011). Moreover, CryAB participates in protein 
degradation pathways. In particular, αB-Crystallin specifically interacts 
both in vitro and in vivo with C8/α7, one of the 14 subunits of the 20S 
proteasome (Boelens WC. et al., 2001).  
As for autophagy, αB-crystallin is involved in chaperone-mediated 
autophagy (CMA). In particular, it acts by increasing degradation of 
misfolded proteins and aggregates (Kannan R. et al., 2012). 
Structurally, αB-Crystallin (CryAB or HspB5) is a small cytosolic protein 
of 175 amino acids. As other sHSPs, it comprises a poorly conserved N-
terminal domain, a highly conserved α-Crystallin domain (ACD), and a 
short C-terminal extension (Fig. 10). The chaperone activity of CryAB is 
affected by post-translational modifications of the N-terminal domain such 
as phosphorylation, oxidation, deamidation, glycation, acetylation, and 
truncation. 
Little is known about the effect of post-translational modifications on the 
CryAB chaperone activity and several studies provide conflicting 
conclusions. In fact, both the influence of these modifications and the 
structure-function relationship of CryAB are still controversial (Nagaraj 
R.H. et al., 2015). 
Phosphorylation is one of the most important post-translational 
modifications. Under conditions of different stresses (heat, ischemia, and 
hypoxia), CryAB is phosphorylated at three serine residues, i.e., 19, 45, and 
59, in vivo, (Fig 10) by different protein kinases: p44/42 MAP kinase 
(ERK) and P38 MAP Kinase (P38). These kinases target Ser-45 and Ser-
59, respectively. However, the signaling pathway leading to 
phosphorylation of serine 19 is currently unknown (Fig 11) (Kannan R. et 
al., 2012).  
The influence of phosphorylation at these residues on the chaperone 
activity of CryAB is controversial. Several studies using phosphorylation 
mimics demonstrate increased phosphorylation leads to the formation of 
smaller oligomeric complexes (Ito H. et al., 2001) and enhances chaperone 
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activity (Ecroyd H. et al., 2007). In contrast, phosphorylation-dependent 
induction of small oligomeric structures reduces CryAB chaperone activity 
(Aquilina J.A. et al., 2004).  
Interestingly, studies in cardiomyocytes and cancer cells found that Ser-59 
phosphorylation of CryAB contributes to maximal apoptosis prevention 
(Launay N. et al., 2010; Morrison L.E. et al., 2003). However, another 
study found that oxidative stress by TNF-α causes CryAB phosphorylation 
at Ser-59 and phosphorylated αB-crystallin associates and increases the 
kinase activity of the IKK complex, thus facilitating phosphorylation and 
subsequent degradation of IkB (Adhikari AS. et al., 2011).  
In addition to phosphorylation, CryAB also undergoes deamidation, which 
is one of the most frequent in vivo modifications during aging and cataract 
development. Deamination not only alters secondary and tertiary structures 
as well as oligomerization properties but also reduces the levels of 
chaperone activity. In particular, the deamidation of an Asn (N) residue at 
position 146 (N146) but not at position 78 (N78) has profound effects on 
the structural and functional properties of CryAB (Gupta R. and Srivastava 
OP. 2004). 
C-terminal truncation is another modification that decreases CryAB 
chaperone activity (Takeuchi N. et al., 2004). However, this type of 
modification alters not only conformation and thermal stability, but also 
susceptibility to degradation by the ubiquitin-proteasome pathway 
(UPP) (Zhang X. et al., 2007). For instance, diabetic lenses show enhanced 
C-terminal truncation, which could lead to increased protein aggregation, 
ultimately causing diabetic cataracts (Thampi P. et al., 2002). 
Glycation is another major modification of CryAB. Glycation by sugars 
and ascorbate reduces chaperone function, whereas glycation by 
methylglyoxal (MGO), a metabolic alpha-dicarbonyl compound, enhances 
its chaperone function (Nagaraj R.H. et al., 2003). 
Acetylation of lysine residues is another important modification that 
increases chaperone activity. In particular, acetylation at K92 in αB-
crystallin increases both chaperone and anti-apoptotic activities (Nahomi 
RB. et al., 2013; Kannan R. et al., 2012). 
All these observations suggest a controversial effect of post-translational 
modifications on the structure and functions of α-crystallin (Nagaraj R.H. 
et al., 2015). 
 
Several mutations have been associated with CryAB. The first, identified 
in 1998, is the R120G, a missense mutation associated with desmin-related 
myopathy and cataracts. In particular, it causes the loss of chaperone 
function and the formation of protein precipitates inside cells. There are 
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other mutations associated with many diseases, such as myopathy, 
neuropathy, ischemia, cataract, and cancer disorders in which the mutated 
form of CryAB fails to protect cells from abnormal protein aggregation 
(Vicart P. et al., 1998). 
A very recent study has intriguingly demonstrated that CryAB assists the 
folding of several multipass transmembrane proteins (TMPs) by interacting 
with their cytosolic face, thereby highlighting the positive function of this 
protein in some genetic diseases, like WD and Familial exudative 
vitreoretinopathy (FZ4-FEVR). In particular, in these two conditions, two 
mutated genes    i.e., ATP7B-H1069Q, a mutant form of the Cu transporter 
associated with WD and Frizzled4-L501fsX533, a frame-shift mutant 
associated with a rare form of FZ4-FEVR    accumulate in the ER and are 
not transported to their final destination (trans-Golgi network and plasma 
membrane, respectively). In the biomolecular scenario of WD, CryAB 
exerts its beneficial action by rescuing proper folding of ATP7B-H1069Q 
and by transporting it to the TGN and post-Golgi vesicles in response to Cu 
overload (Fig. 12) (D’Agostino M. et al., 2103).  
  
 
 
 
Figure 9. Schematic illustration of αB-Crystallin cellular functions. 
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Figure 10. Schematic representation of 3 CRYAB domains and major 
phosphorylation in Serine residues (Ciano M. et al., 2016). 
 
 
 
Figure 11. Structural organization of a-crystallin protein. α-Crystallins have a 
crystallin core domain flanked by variable NTD and CTE. Three known phosphorylation 
sites on αB-crystallin are located in the NTD and can be activated by p44/42 and p38 MAP 
kinases, as well as by other still unknown pathways (Kannan R. et al., 2012). 
 
 
Figure 12. Rescue of localization and response to Cu overload of ATP7B-H1069Q 
by the cytosolic holdase CryAB. ATP7B-H1069Q, assisted by CryAB, folds into the 
proper conformation, moves to the Golgi complex, and responds to Cu overload similarly 
to wild-type ATP7B. 
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1.7  αB crystallin-derived peptides 
   Previous studies have demonstrated that CryAB acts like a molecular 
chaperone and forms a stable complex with partially unfolded proteins. Its 
chaperone activity depends on its binding affinity for target proteins 
(Horwitz J, 1992). Although the molecular mechanisms by which 
chaperones interact with unfolded proteins are still unclear, several studies 
determined the regions involved in its chaperone function. The regions that 
most likely interact with a number of target proteins have been identified 
with a variety of biochemical approaches in vitro (protein crosslinking 
methods). It has been hypothesized that the N-terminal phenylalanine-rich 
region (Plater M. L. et al., 1996) and the hydrophobic sequences in the 
Crystallin domain, as in the case of the molecular chaperone GroEL, are 
responsible for chaperone-like activity. Another study on sHSP αB-
crystallin reports that residues 57–69 and 93–107 in αB-crystallins are 
involved in chaperoning ADH (alcohol dehydrogenase) (Sharma KK. et 
al., 1997; Sharma KK. et al., 2000).  
To determine which site of CryAB retains chaperonic functions, several 
peptides have been synthetized to study their functional activity. The 
synthetic peptides exhibiting chaperone activity have been called “mini-
chaperones” or “mini-αB peptide” (Raju M. et al., 2016). It has been shown 
that the isolated peptides corresponding to residues 73-85 and 101-110 of 
the crystallin domain have anti-fibril formation activity (Ghosh JG. et al., 
2008), whereas peptide 73-92 prevents aggregation and precipitation of 
unfolding proteins, similar to the full-length native α-crystallin 
(Bhattacharyya J. et al., 2006). 
Ghosh and Clark identified additional chaperone peptides representing 
specific regions of CryAB: 73DRFSVNLDVKHFS85, (N terminal domain) 
113FISREFHR120, (N terminal domain) 131LTITSSLSDGV142 (α crystallin 
core domain) and 156ERTIPITRE164 (C-terminal extension) (Ghosh JC. and 
Clark JI. 2005). All these peptides are endowed with chaperone activity 
against partially unfolded ADH. In addition, the minimal sequence of the 
peptide crucial for chaperone activity has been studied to develop effective 
and potent chaperone(s) for therapeutic purposes (cataract, 
neurodegenerative diseases and other protein aggregation disorders). 
However, none of these ‘modified’ peptides exhibit better chaperone 
function than the original mini-αB sequence 73-92. In contrast, deletion of 
DRFS residues from the N-terminal side (mini-αB 77-92) or deletion of 
LKVK from the C- terminal side (mini-αB73-88) of mini-αB completely 
impairs chaperone activity (Raju M. et al., 2016). Other studies have 
demonstrated that the peptide 70KFVIFLDVKHFSPEDLTVK88 in αA-
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crystallin and the peptide 73DRFSVNLDVKHFSPEELKVK92 in αB-
crystallin act as mini-chaperones inhibiting stress-induced aggregation of 
several proteins similar to the parent molecules. In particular, they prevent 
stress-induced apoptosis in mammalian cells by blocking cytochrome c 
release from mitochondria and the caspase-3 and -9 activity. In organ-
cultured rat lenses, the peptides inhibit calcimycin-induced epithelial cell 
apoptosis, whereas intraperitoneal injection of the peptides inhibit cataract 
development in selenite-treated rats, which is accompanied by inhibition of 
protein insolubilization, oxidative stress, and caspase activity in the lens 
(Nahomi RB. et al., 2013).  
Similar results have been obtained with peptides in heat-shock protein 
Hsp20 (G71HFSVLLDVKHFSPEEIAVK91) and Hsp27 
(D93RWRVSLDVNHFAPDELTVK113), with sequence homology to αB-
crystallin. Both peptides exhibit robust chaperone and anti-apoptotic 
activities and inhibit hyperthermic and chemically induced aggregation of 
client proteins. Thus, they may have therapeutic benefits in diseases 
associated with protein aggregation and apoptosis. (Nahomi RB. et al., 
2015). In conclusion, data show that the 20mer peptide 
“DRFSVNLDVKHFSPEELKVK” is the top performing chaperone. This 
sequence, which is highly conserved across many small heat shock proteins 
corresponds to the amino acids 73–92. 
Transport systems that mediate the uptake of oligopeptides have been 
known to exist in mammalian cells. In particular, the oligopeptide 
transporters SOPT1 and SOPT2 (sodium-coupled oligopeptide transport 
system 1 and 2) are the two putative transporters for α-Crystallin peptides. 
Consistently, a recent study by Sreekumar et al., has shown that the mini-
αB 73-92 peptide enters human fetal retinal pigment cells (hfRPE), via 
SOPT1 and SOPT2 and protects them from oxidative stress-induced 
apoptosis; however, a much better protection is provided by the uptake of 
peptide-containing nanoparticles into cells (Sreekumar PG. et al., 2013).  
On the basis of this insightful evidence, my research project set out to 
investigate whether the activity of the mini-αB 73-92 in our WD cellular 
model might act as a chaperone for the folding, localization, and activity of 
ATP7B-H1069Q and work as efficiently as the full-length CryAB.  
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Figure 13. Structural model and primary sequence of CryAB protein and its derived 
peptides. Dashed line: region of the protein for which no crystallographic data are 
available. The N-terminal, α-Crystallin, and C-terminal extension domains are indicated. 
In the crystallin domain, the three major peptides endowed of chaperone activity in vitro 
(73-85, 73-92 and 101-110) are indicated in blue, blue + green, and red, respectively. In 
the red square is indicated the peptide sequence (73-92) mentioned in this thesis. 
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2.   AIMS OF THE THESIS 
   My project carried out in Professor Bonatti's laboratory, in collaboration 
with Simona Allocca, focused on the study of sHSPB5 αB-crystallin 
(CryAB). This sHSP is known for its chaperone activity on the mutated Cu 
transporter ATP7B-H1069Q, the most common cause of WD. Previous 
results obtained from our laboratory have demonstrated that CryAB acts as 
a holdase, thereby preventing improper aggregation and rescuing the Golgi 
complex localization of ATP7B-H1069Q (D’Agostino M. et al., 2013). 
Studies show that this sHsp forms large and dynamic homo- and hetero-
oligomeric complexes that are important in carrying out holdase chaperone 
activity (Arrigo A.P. et al., 2007). However, as of today, the relationship 
between CryAB oligomer size, phosphorylation status, and chaperone 
activities is still controversial (Morrison L.E. et al., 2003). 
Recent studies show that CryAB peptides can also act as mini-chaperones 
in vitro and in vivo, thereby mimicking the effects of full-length protein 
(Sreekumar PG. et al.; Nahomi RB et al., 2015). In effect, compared to 
native proteins, peptides may be more effective because they are smaller, 
may have greater specificity of action, and are more efficiently delivered 
to target tissues. 
It is on the basis of this insightful evidence that my research project set out 
to investigate the activity of the synthetic peptide 73-92 derived from the 
crystallin-domain of CryAB (Peptide1) in our WD cellular model. 
Actually, the rationale behind the project was that this mini-chaperone 
could represent a new and interesting therapeutic alternative to the full-
length protein in rescuing the proper intracellular localization of ATP7B-
H1069Q. In this context, the aims of my project are focused on two lines 
of research.  
 
The first is based on the study of the effects of phosphorylation on CryAB 
full-length structure and function and how phosphorylation can influence 
CryAB chaperone activity on ATP7B mutant. Previous findings have 
shown that phosphorylation of serine residues interferes with the degree of 
oligomerization and the activity of the chaperone (Ito H. et al., 1997). 
Accordingly, we studied the effect of either the single pseudo-
phosphorylated CryAB-S19D, -S45D and -S59D mutants or the double 
pseudo-phosphorylated mutants by using (1) immunofluorescence analysis 
(in cells co-transfected with ATP7B-H1069Q) to verify their rescue ability 
and (2) the glycerol gradient assay to study oligomerization. 
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The second line of research discussed in this thesis is based on CryAB 
dissection in its main domains: N-terminal, α-crystallin, and C-terminal. 
In particular, we assayed each domain through immunofluorescence 
analysis in cells co-transfected with ATP7B-H1069Q to verify their rescue 
ability. Then, we tested the synthetic peptide 73-92 derived from the 
crystallin-domain of CryAB (Peptide1) in our WD cellular model. For this 
purpose, we performed MTT assays, cell growth curves, subcellular 
fractionation, coimmunoprecipitation and immunofluorescence analysis. 
 
In addition, this thesis will discuss the generation of an isogenic cell model, 
based on iPSCs obtained from skin fibroblasts of a homozygous patient 
(H1069Q/H1069Q) and a familiar control (WT/H1069Q), followed by 
differentiation into HLCs. Remarkably, these cells represent a disease 
model that mimics much more closely a WD patient than the hepatoma cell 
lines currently used for transfection.  
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3.   MATERIALS AND METHODS      
 
 
cDNA cloning and plasmid construction 
  
cDNA encoding CRYAB (ID: NM_001885.1) cloned into pCMV6-XL5 
vector plasmid was obtained from Origene. To obtain the construct 
3xFLAG–CryAB, the cDNA coding for CryAB was amplified from 
pCMV6-XL5 plasmid by PCR using the following oligos containing 
HindIII/XbaI flanking restriction sites and cloned into p3xFLAG–CMV-
7.1: 
Fw (HindIII): 59-AAGCTTATGGACATCGCCATCCACCACCC-39;  
Rv (XbaI): 59-TCTAGACTATTTCTTGGGGGCTGCGG-39.  
To obtain the construct 3xFLAG–CryAB (R120G) in which the R120 was 
substituted with a glycine (G), the construct 3xFLAG–CryAB was used as 
a template and site direct mutagenesis was performed according to the 
manufacturer instructions (Roche) using the following oligos: 
Fw: 59-CTCCAGGGAGTTCCACGGGAAATACCGGATCCCAG-39; 
Rv: 59-GTGGAACTCCCTGGAGATGAAACC-39.  
To obtain the construct HA-CryAB, the cDNA coding for CryAB was 
amplified from pCMV6-XL5 plasmid by PCR using the following oligos 
containing HindIII/XbaI flanking restriction sites and cloned into pCDNA3 
expression vector (Invitrogen): 
Fw (EcoRI): 59-GAATTCATGGACATCGCCATCCACCACCC-39; 
Rv (XhoI): 59-CTCGAGCTATTTCTTGGGGGCTGCGG-39.  
DNA of ATP7B and ATP7B-H1069Q GFP-tagged at the N-terminus was 
provided by Svetlana Lutsenko (John Hopkins Medical School, Baltimore, 
MD) and by Dominik Huster (Otto-von-Guericke-University, Magdeburg, 
Germany). 
 
 
Cloning strategy 
 
N-terminal (NTD), α-crystallin (ACD) and C-terminal domains (CTE) 
were amplified using the Expand High Fidelity PCR System (Roche) and 
specific primers: 
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NTD: FW - 5’-GAATTCATGGACATCGCCATCCACC-3’ 
          REV- 5’CTCGAGCTATGAGAGAGTCCAGTGTCAAACC-3’ 
ACD: FW - 5’-GAATTCCTCTCAGAGATGCGCCTGG-3 
          REV: 5’CTCGAGCTAATTCACAGTGAGGACCC-3’ 
CTE: FW: 5’-GAATTCCCAAGGAAACAGGTCTCTG-3’ 
          REV: 5’-CTCGAGCTATTTCTTGGGGGCTGC-3’ 
The forward primers contain the restriction enzyme EcoRI recognition site, 
while the reverse primers contain the restriction enzyme XhoI recognition 
site. In the reverse primers used for the amplification of N-terminal and α-
crystallin domains is also present a stop codon. Restriction enzymes EcoRI 
and XhoI recognition sites are compatible with the multiple cloning sites 
on the HAN(I)-pcDNA3 expression vector. Amplified gene was cloned 
into pCR 2.1-TOPO cloning vector (Invitrogen) and transformed into 
TOP10 Escherichia coli (E. coli) cells. Transformed cells were selected on 
a LB plate containing 100 µg/mL ampicillin at 37°C for 16-18 hours. 
Positive transformants were inoculated into LB broth containing 100 
µg/mL ampicillin for plasmid propagation. Plasmid was isolated and the 
presence of the DNA fragment of interest was determined by restriction 
enzyme digestion and DNA sequencing. The TOPO vector containing the 
DNA fragment of interest and the expression vector were then digested 
with the same enzymes (EcoRI and XhoI) to generate the same sticky ends. 
The digestion products of both the DNA fragment of interest and the 
expression vector were ligated at room temperature for 5 minutes using the 
Rapid DNA Ligation Kit (Roche). Ligated mixture was transformed into 
TOP10 E. coli cells and selected using the same strategies as described 
above. 
 
 
Cell culture 
 
   Cells were maintained in 5% CO2 at 37°C in a humidified chamber. The 
COS7 (monkey kidney fibroblast-like cells) cell line was grown in 
Dulbecco’s modified essential medium (DMEM), supplemented with 10% 
of fetal bovine serum (FBS), 1% L-Glutamine and 1% 
Penicillin/Streptomycin. HepG2 (human epatocellular carcinoma) cell line 
knockout for the expression of ATP7B (HepG2 KO), kindly provided by 
Roman Polishchuk, was routinely grown in Roswell Park Memorial 
Institute (RPMI) medium, containing 10% fetal bovine serum (FBS), 1% 
                                                                                             3. Materials and methods 
 
   27  
L-Glutamine and 1% Penicillin/Streptomycin. ATP7B knockout was 
obtained by highly specific ZFN directed mutagenesis (Porteus MH. and 
Carroll D. 2005; Chandhok G. et al., 2014). Huh7 (human epatocellular 
carcinoma) cell line was grown in Dulbecco’s modified essential medium 
(DMEM), supplemented with 10% of fetal bovine serum (FBS), 1% L-
Glutamine and 1% Penicillin/Streptomycin. 
 
 
Transfection 
 
   COS7, Huh7, or HepG2 KO cells were cultured on a coverslip in 24 well 
plates and after 24 hours were transfected with X-tremeGene HP 
Transfection Reagent (Roche) and JetPEI-Hepatocyte DNA Transfection 
Reagent (Polyplus transfection), respectively, according to the 
manufacturer’s instructions.  
 
 
Viral transduction 
 
HepG2 KO cells were cultured on a coverslip in 24 well plates and after 
24 hours were infected with an adenovirus carrying GFP-ATP7B-H1069Q. 
Human adenovirus type 5 (dE1/E3) was produced by Vector Biolabs in 
HEK 293 as packaging cells and CMV promoter drives the expression of 
GFP-ATP7B-H1069Q. 
 
 
Peptide treatment 
 
Peptide1 (H-Asp-Arg-Phe-Ser-Val-Asn-Leu-Asp-Val-Lys-His-Phe-
Ser-Pro-Glu-Glu-Leu-Lys-Val-Lys-OH), Peptide2 or Ctrl Peptide (H-Lys-
Val-Lys-Leu-Glu-Glu-Pro-Ser-Phe-His-Lys-Val-Asp-Leu-Asn-Val-Ser- 
Phe-Arg-Asp-OH), and Peptide3 or Ctrl Pept (H-Asp-Leu-Pro-Leu-Lys-
Val-Asn-Val-Glu-Asp-Lys-Phe-His-Arg-Ser-Phe-Val-Glu-Ser-Lys-OH) 
were chemically synthesized by GL Biochem (Shanghai, China) and were 
then resuspended in H2O to obtain a final concentration of 5 mM. 
Synthetic peptides were labeled or not with TAMRA at the side chain 
amino group of Lysine residue at the Carboxy (Peptide1 and Peptide3)) and 
Amino terminal ends (Peptide2).  All the peptides, resuspended in steril 
H2O (25%) and RPMI or DMEM (75%), were added in the cell culture 
medium at a final concetration of 12,5 µM for 24 hours. 
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Copper treatment 
 
COS7 cells, seeded on coverslips in 24 well plates, were transfected with 
pEGFP-C1-ATP7B WT or pEGFP-C1-ATP7B-H1069Q and treated with 
Pept1 or Ctrl Pept, as mentioned above.  After 48 hours, 200 µM of CuSO4 
or 500 µM of BCS, was added to the cell culture medium for 2 hours. Then, 
the cells were subjected to indirect immunofluorescence procedure as 
below. Single confocal images were acquired at 63X magnification on a 
LSM510 Meta confocal microscope (Carl Zeiss, Jena, Germany). 
 
 
Immunofluorescence analysis 
 
COS7 or Huh7 cells were fixed in formaldehyde 3.7% for 30 minutes, 
washed with PBS 1X, and permeabilized with 0.1% Triton in PBS 1X. 
Non-specific signals were blocked in 1% BSA in PBS 1X for 15 minutes. 
The cells were then incubated for 1 hour with the following primary 
antibodies: anti-GOLGA2 (rabbit polyclonal, Sigma Aldrich) or anti-
TGN46 (rabbit polyclonal, Sigma Aldrich) to visualize Golgi complex, 
anti-Lamp1 (mouse monoclonal, DSHB) to visualize lysosomes, and anti-
Flag (mouse monoclonal, Sigma Aldrich) or anti-HA (mouse monoclonal, 
Sigma Aldrich). Next cells were washed three times in PBS 1X and 
incubated with Alexa Fluor 546-labelled anti-mouse and Alexa Fluor 633-
labelled anti-rabbit secondary antibodies (Thermo Fisher) at room 
temperature for 45 minutes. Finally, nuclei were stained with Dapi (Sigma 
Aldrich). Single confocal images were acquired at 63X magnification on a 
LSM510 Meta confocal microscope (Carl Zeiss, Jena, Germany). 
 
 
MTT assay 
 
COS7 or HepG2 KO cells were plated in 96-well plates and, after 24 
hours, exposed to 12.5 µM of Pept1 or Ctrl Pept. At the indicated time 
points, 10 µl of 5 mg/ml MTT solution was added to each well for 4 h at 
37°C. After removal of the medium, 100 µl of isopropanol plus 0,1M HCl 
was added to each well to dissolve formazan crystals. The absorbance at 
570 nm was determined with the SYNERGY H1 microplate reader (Bio-
Tek Instruments, Inc, Winooski, VT, USA). Triplicate wells were assayed 
for each condition and the S.D. was determined. 
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Cell-growth assay 
 
HepG2 KO cells were seeded in 24 well plates. After 24 hours, they 
were treated with Pept1 or Ctrl Pept. Cell counts were performed in a 
Burker chamber, after 24, 48, and 72 hours from the treatment. After 72 
hours, cells were replated in 12 well plates and peptides were 
readministered. Cell count was performed 72 hours later. 
 
 
Differential centrifugation 
 
COS7 cells were plated in p60 dishes. One day after growth, cells at 
80% confluence were treated with TAMRA-labeled Pept1 or Ctrl Pept. 
After 24 hours, the cells were resuspended in lysis buffer (10 mM Tris-HCl 
pH 7.4, 150 mM NaCl pH 8.0, 1 mM EDTA ph 8.0, protease inhibitors), 
incubated 30 minutes on ice, and then lysed by sonication. The samples 
were centrifuged at 16.000xg at 4°C for 30 minutes, the pellets resuspended 
in lysis buffer, and the supernatants centrifugated at 100.000xg at 4°C for 
30 minutes. Finally, the pellets were resuspended in lysis buffer 
supplemented with 1% Triton. All the pellets and the supernatants obtained 
from the 100.000xg centrifugation were analyzed by spectrofluorimeter.  
 
 
Co-immunoprecipitation 
 
   COS7 cells were cultured in P100 plates and, after 24 hours, were 
transfected with pEGFP-C1-ATP7B-H1069Q, using X-tremeGene HP 
(Roche, Milan, Italy), according to the manufacturer’s instructions. The 
next day, they were treated with 12.5 µM of TAMRA-labeled Pept1 or Ctrl 
Pept for 24 hours. Then, cells were lysed with 10 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1 mM EDTA pH 8.0, 1% Triton X-100 and 1X Protease 
inhibitors (Roche). Immunoprecipitation was performed by overnight 
incubation at 4°C with mouse monoclonal anti-GFP antibody (Invitrogen), 
followed by addition of Protein A- Sepharose beads (Roche). The 
immunoprecipitated samples were analyzed through Mass Spectrometry 
(MS) by Chiara D'Ambrosio in the laboratory of Professor Scaloni at 
ISPAAM, Naples. 
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Mass spectrometry 
 
   Proteins/peptides were extracted from the beads with an aqueous 5% 
formic acid solution. The supernatants were transferred onto Centricon 
devices (3 kDa cutoff) (Millipore) and filtered by centrifugation at 14.000 
g for 30 min. Resulting samples were dryed and vacuumed, and then 
analyzed with a nanoLC-ESI-Q-Orbitrap MS/MS system, consisting of an 
UltiMate 3000 HPLC RSLC nano system-Dionex coupled to a Q-
ExactivePlus mass spectrometer through a Nanoflex ion source (Thermo 
Fisher Scientific).  
Peptides were loaded on an Acclaim PepMapTM RSLC C18 column (150 
mm × 75 µm ID, 2 µm - particles, 100 Å - pore size (Thermo Fisher 
Scientific), and eluted with a gradient of solvent B (19.92/80/0.08 v/v/v 
water/acetonitrile/formic acid) in solvent A (99.9/0.1 v/v water/formic 
acid) at a flow rate of 300 nL/min. The gradient of solvent B started at 3%, 
increased to 10% over 5 min, increased to 30% over 40 min, rose to 80% 
over 5 min, remained at this percentage for 14 min, and finally returned to 
3% in 1 min, remaining so for 30 additional minutes. The mass 
spectrometer operated in Selected Ion Monitoring (SIM) mode setting 
m/z=560.69 ±0.6 (charge 5+) with nominal resolution of 70000, automatic 
gain control target of 50000, and a maximum ion target of 100 ms, followed 
by MS/MS scans of the most abundant ion. MS/MS spectra were acquired 
in a scan m/z range 120-2000 using a normalized collision energy of 32%, 
an automatic gain control target of 200000, a maximum ion target of 100 
ms, and a resolution of 17500. Two biological replicates were analyzed.  
 
 
Western blot analyses and Chx treatment of HepG2 KO and HLCs 
 
   HepG2 KO cells were cultured in 6 well plates, infected with an 
adenovirus carrying GFP-ATP7B-H1069Q, and incubated with Pept1 or 
Ctrl Pept, as previously mentioned. Then, they were treated with or without 
100uM of cycloheximide (Sigma) for 2 hours, and subsequently lysed with 
10 mM Tris-HCl pH 7,4, 150 mM NaCl, 1 mM EDTA pH 8, 1% Triton X-
100 supplemented with cock-tail protease inhibitors (Roche Diagnostics).  
Protein concentration was finally determined by Bradford assay (Bio-Rad). 
Denaturation and reduction of protein samples of SDS-PAGE was 
performed at 37°C for 30 minutes. For each sample, 35 ug of total protein 
was loaded into 8% SDS gel and blotting was performed using a 0.45 µm 
nitrocellulose membrane (GE Healthcare). The blots were blocked for 1 
hour with 5% non-fat dry milk prepared in TBST (10 mmol/L Tris (pH 8), 
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150 mmol/L NaCl, 0.1% Tween 20). They were subsequently incubated 
with primary antibodies for GFP (rabbit polyclonal, Abcam) and Tubulin 
(mouse monoclonal, Abcam) as a protein loading control, for 1 hour at 
room temperature. After that, they were washed three times in TBST and 
further incubated for 1 hour with secondary antibodies HRP-conjugated 
goat anti-rabbit (Santa Cruz) and anti-mouse IgG (Santa Cruz). Bound 
antibodies were detected by the ECL detection system (Santa Cruz). 
Densitometric analysis was performed using ImageJ 1.47v software. 
 
 
iPSC generation 
 
   To generate iPSCs, 1 × 106 fibroblasts were transfected with a total of 
1 µg of each episomal plasmids containing pCXLE-hOCT3/4-shp53-F, 
pCXLE-hSK, pCXLE-hUL (Addgene) (Okita K. et al., 2011)    a more 
efficient method to generate integration-free human iPS cells. 
Electroporation was carried out using a Nucleofector™ 2b Device (Lonza) 
employing NHDF Nucleofector Kit (Lonza), following the manufacturer’s 
instructions. After electroporation, the cells were cultured for 4 days in 
fibroblast medium and were then plated on mitomycin inactivated 
fibroblasts (feeder). The next day, the medium was switched to hES 
medium as follows: KO-DMEM, 20% Knock-out acids, 50 U/ml 
(penicillin and 50 mg/ml streptomicin),100 µM 2-mercaptoethanol (all 
from Invitrogen), and 10 ng ml-1 bFGF (Peprotech). The medium was 
changed on alternative days until the formation of iPSC colonies (20-22 
days). Then, individual iPSC colonies were manually picked and 
transferred to a new dish on mitomycin inactivated fibroblasts. The iPSCs 
were expanded by splitting them with collagenase (Invitrogen) and then 
frozen in liquid nitrogen in FBS (Hyclone) containing 10% DMSO 
(Sigma). To remove feeder from iPSC clones, the cells were grown for 
multiple passages (>5) on Matrigel (BD Biosciences) coated plates in 
mTeSR medium (Stem cell technologies).  
 
 
Generation of HLCs from iPSCs 
 
   To generate hepatocytes from both control and patient iPSC clones, we 
employed an already described method that enables the efficient production 
of HLCs (Si-Tayeb K, et al., 2010). Briefly, iPSC clones were plated on 
Matrigel and cultivated for 20-22 days. The media composition was 
changed as follows: 5 days in RPMI media supplemented with B27 and 
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100ng/ml of Activin A (R&D), 5 days in RPMI media supplemented with 
20ng/ml BMP4 (R&D) and 10ng/ml bFGF (Preprotech), 5 days in RPMI-
B27 supplemented with 20ng/ml hepatocyte growth factor (HGF, 
Invitrogen), and, finally, further 5-7 days in hepatocyte culture medium 
(Lonza) supplemented with 20ng/ml Oncostatin M (Invitrogen). 
 
 
Immunofluorescence of hiPSCs and HLCs 
 
   hiPSCs were fixed in 4 % paraformaldehyde, permeabilized with 0.2 % 
TX-100 in 10 % FBS/1 % BSA in 1× PBS for 7 minutes at room 
temperature; non-specific signals were blocked in 10 % FBS/1 % BSA in 
1× PBS for 30 minutes at room temperature. Thus, the cells were incubated 
with primary antibodies in 10 % FBS/1 % BSA in 1× PBS over night at 
4°C. The following primary antibodies were used: anti-Oct4 (Santa Cruz), 
anti-Nanog (Cell Signaling), anti-alpha-fetoprotein (AFP) (Abcam), and 
anti-alpha-1 antitripsin (AAT) (Dako). After primary antibody incubation 
and washes in 1X PBS, the cells were incubated with the Alexa- Fluor 488 
or 594 secondary antibodies (Molecular Probes) and the nuclei were stained 
with Dapi (Calbiochem). Cells were visualized with a 20×/0.40 (dry lens) 
objective using an inverted microscope (DMI4000, Leica Microsystems) at 
room temperature in 1× PBS. The images were captured with a digital 
camera (DFC365 FX, Leica Microsystems) using LAS-AF software (Leica 
Microsystems). 
 
 
Preparation of cell extracts, SDS-PAGE and Western blot analysis of 
HLCs 
 	  	  	  	  After 20 days of differentiation, HLCs from control and patient iPSCs 
were treated with or without 100µM cycloheximide (Sigma) for the 
indicated time period. Cells were lysed with lysis buffer containing 10 mM 
Tris-HCl pH 7,4, 150 mM NaCl, 1 mM EDTA pH 8, and 1% Triton X-100 
supplemented with cock-tail protease inhibitors (Roche Diagnostics); 
protein concentration was finally determined by Bradford assay (Bio-Rad). 
Denaturation and reduction of protein samples of SDS-PAGE was 
performed at 37°C for 30 minutes. For each sample, 35 ug of total protein 
was loaded into 8% SDS gel and blotting was performed using a 0.45 µm 
nitrocellulose membrane (GE Healthcare). The blots were blocked for 1 
hour with 5% non-fat dry milk prepared in TBST (10 mmol/L Tris (pH 8), 
150 mmol/L NaCl, 0.1% Tween 20). They were subsequently incubated 
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with primary antibody for ATP7B (rabbit polyclonal, Abcam) and Actin 
(rabbit polyclonal, SIGMA) as a protein loading control, for 1 hour at room 
temperature. Blots were washed thrice in TBST and further incubated for 
1 hour with secondary antibodies HRP-conjugated goat anti-rabbit (Santa 
Cruz) and anti-mouse IgG (Santa Cruz). Bound antibodies were detected 
by the ECL detection system (Santa Cruz). Densitometric analysis was 
performed using ImageJ 1.47v software. 
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4.   RESULTS 
  
  
4.1   Generation of phosphomimic and phosphodeficient CryAB forms 
 
   We investigated the effects of phosphorylation on the chaperone activity 
of CryAB against misfolded TMPs. To this aim, we generated 
phosphomimic and phosphodeficient constructs of CryAB with an N-
terminal FLAG tag by replacing the relevant serine residues with aspartic 
acid through site-directed mutagenesis. As shown in Fig. 14, the serine 
residues in position 19, 45, and 59 were all substituted with aspartic acid 
(CryAB-S3D) to mimic phosphorylation or with alanine residues (CryAB-
S3A) to prevent it. Moreover, we further mutagenized the CryAB-S3A 
construct to generate either the single pseudo-phosphorylated CryAB-
S19D, -S45D and -S59D mutants or the double pseudo-phosphorylated 
CryAB-S19/45D, -S19/59D and -S45/59D. Such procedure, allowed us to 
discern between the functional contribution of the single phosphomimetic 
residues and the coupled residues, having previously prevented 
prophorylation at the other relevant serines. In addition, as a negative 
control for CryAB chaperone activity, we generated and used CryAB-
R120G, a mutant defective in chaperone activity causing aberrant desmin 
folding and consequent related myopathy (Treweek T.M. et al., 2005). 
 
 
 
Figure 14. Diagram of the mutant forms of CryaB generated and used this thesis. The 
position of the relevant serine residues and arginine 120, and the boundaries between the 
domains are indicated. NTD, ACD, and CTE: N-terminal, Crystallin and C-terminal 
domains, respectively. 
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4.2 Mimicking phosphorylation of αB-CryAB affects its chaperone 
function 
   In a previous study, we demonstrated that ATP7B-H1069Q, assisted by 
CryAB but not CryAB-R120G, folds into the proper conformation, moves 
to the Golgi complex, and responds to Cu overload in the same manner as 
wild-type ATP7B in COS7 cells (D’Agostino M. et al., 2013). This 
ATP7B-H1069Q mutant accumulates in the ER as misfolding aggregates 
(Dmitriev O.Y, et al., 2011). Thus, to evaluate the effects of 
phosphorylation on CryAB chaperone activity, COS7 cells were either 
transiently transfected to express GFP-tagged ATP7B or ATP7B-H1069Q 
or co-transfected with wild-type CryAb, -R120G, or CryAB pseudo-
phosphorylation mutants (Fig. 14). Confocal immunofluorescence 
microscopy showed that the ATP7B-H1069Q was mislocalized in 
comparison to ATP7B, which for the vast majority resides in the Golgi 
complex (Fig. 15 A, B). CryAB-S3A did not affect chaperone activity, 
thereby promoting ATP7B-H1069Q rescue to the Golgi as efficiently as 
the wild-type CryAb (Fig. 15 C, E). By contrast, CryAB-S3D exhibited 
only residual rescuing activity, thereby mimicking the inactive mutant -
R120G (Fig. 15 D, F). At this point, we wondered which of the three serine 
residues, when phosphorylated, could equally and/or additively contribute 
to the negative regulation of the chaperone function. Interestingly, CryAB-
S19D and -S45D showed only residual activity (Fig. 15 G, H), whereas the 
-S59D mutant was fully active (Fig. 15 I). Co-immunoprecipitation 
experiments showed that the phosphomimic constructs of CryAB-S19, -
S45, -S59, and -S3D, as well as -R120G, bound to ATP7B-H1069Q, thus 
suggesting that the lack of activity was not due to loss of binding 
(D’Agostino M. et al., 2013).  
Next, to generalize these results, we performed the same experiment using 
the Frizzled4 (Fz4) receptor mutant (Fz4-FEVR), which is associated with 
a rare form of Familial exudative vitreoretinopathy (FEVR). In this mutant, 
a frameshift mutation (L501fsX533) generates a different and shorter C-
terminal cytosolic tail of the receptor that accumulates in the ER of 
transfected cells (Robitaille J. et al., 2002), preventing it from reaching the 
PM as does the wild-type FZ4. In this regard, we have previously shown 
that CryAB prevents the formation of inter-chain disulfide bridges of FZ4-
FEVR aggregates in the ER, allowing for correct folding and appropriate 
localization on the PM of this mutant (D’Agostino M. et al., 2013). In 
particular, in the presence of CryAB, FZ4-FEVR is almost fully rescued to 
the PM. By contrast whereas only a minor rescue was observed when 
CryAB-S3D, -S19D or -S45D replaced CryAB, both CryAB-S3A and -
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S59D exhibited a strong rescue effect, only slightly below the wild type 
(Fig. 16). These findings strongly confirmed those obtained with ATP7B-
H1069Q, suggesting that phosphorylation plays a pivotal role in CryAB 
chaperone activity toward TMPs.  
Next, we asked whether different combinations of pseudo-phosphorylation 
could differently affect CryAB chaperone function. To this end, we 
generated double pseudo-phosphorylated mutants of CryAB (Fig. 17) 
assayed for chaperone activity by co-transfection with the ATP7B-H1069Q 
in COS7 cells. We demonstrated that the S19/45D resulted almost inactive 
whereas both S19/59D and S45/59D were close to the full active wild type 
CryAB. These results indicate not only that pseudo-phosphorylated S19 
and S45 have an exclusive inhibitory role, but also that pseudo-
phosphorylation at S59 has a protective effect toward the single pseudo-
phosphorylation of S19 and S45, but not toward both simultaneously. 
                                                                                                                       4. Results 
 
   37  
 
 
 
Figure 15. CryAB-S59D restores ATP7B-H1069Q localization in the Golgi complex, 
whereas CryAB-S19D, CryAB-S45D and the triple pseudo-phosphorylated CryAB-
S3D do not. COS-7 were co-transfected to express the indicated GFP-ATP7B forms (first 
column on the left) and the indicated 3xFLAG-tagged CryAB constructs or the control 
empty vector (second column from the left). 48 h post-transfection immunofluorescence 
analyses were performed. The anti-Golgin polyclonal GOLGA2 antibody was used to 
visualize the Golgi complex (third column from the left). Colocalization of GFP and 
GOLGA2 signals was determined with the ImageJ; the obtained Pearson's R value is 
shown on the right (mean ± s.d., n. 10 cells of randomly selected fields from two 
independent experiments). Scale bar: 10 µm (Ciano M. et al., 2016).  
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Figure 16. CRYAB-S59D restores FZ4-FEVR localization in the plasma membrane, 
whereas CRYAB-S19D, CRYAB-S45D, and the triple pseudo-phosphorylated 
CRYAB-S3D do not. Huh-7 cells were co-transfected to express the indicated HA-tagged 
FZ4 forms (first two columns on the left) and the indicated 3xFLAG-tagged CryAB 
constructs or the control empty vector (third column from the left). 48 h post-transfection 
the immunofluorescence analyses were performed to evaluate the presence of FZ4 forms 
on the PM. The histogram on the right shows for each row the surface ratio versus 
intracellular labeling (OUT/IN) of the FZ4 forms normalized to FZ4 wild type (mean ± 
s.d., n. = 10 cells from randomly selected fields of two independent experiments). Scale 
bar: 10 µm (Ciano M. et al., 2016).  
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Figure 17. The pseudophosphorylated S59D protects CryAB chaperone activity in 
double pseudophosphorylated mutants. Cells were manipulated and analyzed as in Fig. 
15 (Ciano M. et al., 2016). 
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4.3 Pseudo-phosphorylation reduces the oligomerization state of CryAB  
   Previous studies have reported that CryAB chaperone activity, similarly 
to Hsp27, is correlated with the size of its oligomeric complexes (Aquilina 
J.A. et al., 2004; Ito H. et al., 2001; Arrigo A.P. et al., 2007). Because 
phosphorylation of serine residues negatively interferes with the degree of 
oligomerization and chaperone activity (Bakthisaran R. et al., 2016), we 
asked whether the different contribution of phosphorylated serines to 
CryAB chaperone activity could derive from a diverse impact on the 
oligomerization state of the chaperone. To answer this question, we 
transiently trasfected cells with different phosphomimetic mutants and 
analyzed them by sedimentation assay in glycerol gradient, SDS-PAGE, 
and immunoblotting. The results showed that (Fig. 18), almost 2/3 of total 
CryAB sediments in the heavier region of the gradient, as well as CryAB-
R120G. Most important, whereas CryAB-S3D is slightly enriched in the 
lighter region, CryAB-S3A is equally present in the two regions. 
Interestingly, all three single phosphomimetic mutants -S19D, -S45D, and 
-S59D are clearly enriched in the lighter fractions. The two pseudo-
phosphorylated CryAB-S19D and –S45D single mutants show only 
residual activity (Fig. 15G, H), while the –S59D mutant results fully active 
(Fig. 15 I). Thus, the inhibitory effect seen for S19 and S45 cannot be 
ascribed to the reduction of oligomerization. Altogether, these data 
demonstrate that the reduction of the oligomerization state of CryAB does 
not correlate with the inhibition of its chaperone activity, suggesting a 
direct role, yet to be elucidated, of phosphorylation in controlling CryAB 
chaperone activity. 
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Figure 18. All pseudophosphorylated CryAB forms determine the formation of 
smaller oligomeric complexes. COS7 cells were transfected to express the indicated 
3xFLAG-tagged CryAB forms. Forty-eight hours post-transfection, the cells were lysed 
and aliquots of the cell extracts were analyzed on of 20-40% glycerol gradients. The 
gradients were collected in 12 fractions (fraction 13 is the resuspended pellet) and the 
protein content resolved on 12% SDS-PAGE followed by immunoblotting to detect 
CryAB (25kDa). One representative immunoblotting result is shown. Quantitative 
analysis of the distribution of CryAB forms in fractions 1-6 and 7-13 of the glycerol 
gradients (mean ± s.d., n. = 3-6 independent experiments) is shown in the histogram below 
(Ciano M. et al., 2016).   
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4.4  α-Crystallin domain rescues Golgi localization of ATP7B-H1069Q 
mutant 
 
Since D’Agostino et al. demonstrated that CryAB is able to interact with 
ATP7B-H1069Q and rescue its proper intracellular localization 
(D’Agostino M. et al., 2013), we set out to identify which specific region 
of CryAB maintains this functional role (chaperone activity). A previous 
report showed that the isolated domains maintain some level of chaperone 
activity in vitro (Asomugha CO. et al., 2011). Accordingly, we dissected 
CryAB in its main domains. N-terminal (NTE), α-crystallin (ACD), and C-
terminal (CTE) domains (residues 1-66, 65-146, 148-175, respectively) 
were cloned in a HAN(I)pcDNA3 vector to generate HA-tagged constructs. 
Then, to determine which CryAB domains were able to rescue Golgi 
localization of ATP7B mutant, we transiently transfected COS7 to express 
GFP-tagged ATP7B or ATP7B-H1069Q or co-transfected them with wild-
type CryAb or HA-tagged CryAB. Confocal immunofluorescence analysis 
revealed that when ATP7B-H1069Q is co-transfected with the N-terminal 
(NTE) or C-terminal (CTE) domain, no rescue effect is obtained as the 
mutated protein is retained in the ER. In contrast, the α-crystallin domain 
(ACD) markedly recovers the intracellular compartmentalization of 
ATP7B-H1069Q, as evidenced by its high expression in the Golgi (Fig. 
19). These results strongly suggest that only the α-crystallin domain (ACD) 
is able to rescue ATP7B-H1069Q Golgi-localization as efficiently as the 
full-length CryAB. To further confirm these data, we evaluated the 
colocalization of GFP and GOLGA2 signals with the ImageJ colocalization 
plugin; the obtained Pearson's R value is shown in the histogram below. 
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Figure 19. α-Crystallin domain corrects localization of ATP7B-H1069Q from the ER 
to the TGN. COS7 cells were transfected to express GFP-tagged ATP7B or ATP7B-
H1069Q or co-transfected with HA-CryAB or its domains (HA-NTE, HA-ACD and HA-
CTE respectively). The histogram shows the colocalization of GFP and GOLGA2 signals 
determined with Pearson's R using the ImageJ software (mean ± s.d., n. 10 cells of 
randomly selected fields from two independent experiments). Scale bar: 10 µm. 
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4.5  CryAB peptide does not affect cell viability 
  
   In light of previous results, it is clear that CryAB crystallin-domain, as 
well as the full-length protein, is able to counteract aggregation and to 
rescue the proper intracellular localization of the mutated Cu transporter 
ATP7B-H1069Q (D’Agostino M. et al., 2013). Furthermore, several 
papers have also demonstrated that CryAB peptides derived from the 
crystallin domain exert a holdase activity in vitro. Most important, CryAB 
peptide corresponding to residues 73-92 protects human lens epithelial 
(HLE) cells from thermal stress-induced apoptosis and inhibits selenite-
induced cataracts after intraperitoneal injection in rats (Nahomi et al., 
2013). Based on this evidence, we used the syntetic peptide 73-92 
(Peptide1) and control peptides (Peptide2, inverted sequence; Peptide3, 
scrambled) to verify whether this CryAB-derived peptide was able to 
mimic the effect of the crystallin domain and the full-length protein on 
ATP7B-H1069Q. To this aim, we either labeled or unlabeld these peptides 
with TAMRA at the side chain amino group of Lysine residue at the 
carboxy (Pept1) and amino terminal ends (Ctrl Pept), respectively (Fig. 20).  
In brief, to assess whether the peptide 73-92 and the control peptide were 
toxic to our cellular systems, we performed an MTT assay on two different 
cell lines: COS7 and HepG2 KO. These cells were incubated with 12.5 µM 
of Pept1 and Ctrl Pept for 96 and 120 hours. We observed that in both 
COS7 and HepG2 cells, Pept1 and Ctrl Pept did not affect cell viability at 
the indicated times of incubation compared to untreated cells (Fig. 21). 
Then, to further confirm these data, we set up a cell growth curve by 
treating HepG2 cells with either Pept1 or Ctrl Pept. Cells were counted 
after 24, 48 and 72 hours. After 72 hours, peptides were readministered and 
cells were recounted two days later. After each count, we found that both 
peptides did not impair cell division and proliferation, thereby strongly 
indicating that peptide treatment is safe for the cellular systems used and, 
more broadly, for our particular cellular system (Fig. 21).  
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Figure 20. αB-Crystallin–derived mini-peptides. Schematic representation of αB-
crystallin-derived peptide sequence (Pept1) and the control peptides (Peptide2, inverted 
sequence; Peptide3, scrambled) labeled or unlabeled with TAMRA. 
 
  
Figure 21. CryAB peptide does not affect cell viability. Cell survival of COS7 and 
HepG2 KO cells was determined by MTT assay after 72, 96, and 120 hours of peptide 
exposure (graphs above) and by cell count after 24, 48, 72, 120 hours of peptides exposure 
in HepG2 KO cells (graph below). MTT assay revealed that peptides treatment did not 
reduce cell viability. No significant differences were observed in the increase of cellular 
number after prolonged peptide exposure in comparison with the control. MTT and growth 
curve data are represented as mean ± s.d of at least 3 indipendent experiments.  
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4.6  Internalization of CryAB peptide 
 
   Since CryAB and control peptides do not impair cell viability, we asked 
whether these peptides could be internalized by the cells. To answer this 
question, we incubated COS7 cells with 12.5 µM of TAMRA labeled Pept1 
and Ctrl Pept for 1, 4, and 20 hours. Using confocal immunofluorescence 
microscopy, we observed that the peptide fluorescent signal became 
cytosolic after about 4 hours and partially colocalized with the lysosomal 
marker LAMP-1 after 20 hours (Fig. 22) (Allocca Simona’s Ph.D thesis. 
New Therapeutic Perspectives for the Most Frequent ATP7B Mutation in 
Wilson Disease: Development of Pharmacologically Active Peptides and 
Generation of a Novel WD Isogenic Cell Model). 
 
 
 
Figure 22. Peptide fluorescent signal colocalizes with the lysosomal marker. COS7 
cells were incubated with 12.5 µM of TAMRA-labeled Pept1 and Ctrl Pept at the indicated 
times. Confocal immunofluorescence analysis were performed with an anti-LAMP1 
protein antibody to visualize the lysosomes. Peptide fluorescent signal was evident in the 
cytosol after about 4 hours and co-localization with LAMP1 was predominant after 20h. 
Scale bar: 10 µm. 
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4.7 Peptide localizes mainly in the cytosol of COS7 cells 
   To further study the intracellular localization of the CryAB peptide, we 
performed a subcellular fractionation by differential centrifugation 
followed by spectrofluorimetric analyses. In particular, we fractionated 
cellular extracts from COS7 cells (Fig. 23 A) treated with 12.5 µM of 
TAMRA-labeled Pept1 and Ctrl Pept for 20 hours. Then, we analyzed the 
fluorescence emission of each fractions by spectrofluorimetry. As shown 
in Fig. 23 B, we found about 60% of both peptides in the S100 (cytosol) 
and about 10% in the P100 (particulate) fractions, thus confirming our 
immunofluorescence data. These results suggest that although CryAB and 
control peptides are mainly cytosolic, they are also partially present in the 
vescicular compartments. The uptake mechanism requires further 
investigations (Allocca Simona’s Ph.D thesis). 
 
 
                         
  
  
Figure 23. Peptide localizes mainly in the cytosol fraction. Cells were incubated with 
12.5 µM of TAMRA-labeled Pept1 and Ctrl Pept for 24h, lysed, and then separated into 
subcellular fractions using differential centrifugation. Fluorescence emission of each 
fraction was determined by spectrofluorimeter and reported as percentage of P16, S100, 
P100 in the graph below. 
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4.8 Pept1, but not Ctrl Pept, rescues the Golgi localization of ATB7B- 
H1069Q 
   To assess whether CryAB-derived peptides were able to rescue the proper 
localization of ATP7B-H1069Q, as already seen with the crystallin domain 
and the full-length protein, COS7 cells were either transfected to express 
GFP-tagged ATP7B and ATP7B-H1069Q, or co-transfected with wild-
type CryAB as control. Next, these cells were treated with Pept1 and Ctrl 
Pept conjugated or unconjugated to TAMRA for 24 hours post transfection. 
We found that GFP-ATP7B wild type was expressed mainly in the Golgi 
complex, as indicated by co-localization with GOLGA2 marker (blu 
staining), whereas GFP-ATP7B-H1069Q was mainly expressed in the ER 
(Fig. 24). Therefore, we concluded that in cells expressing ATP7B-
H1069Q and co-transfected with the full-length CryAB or treated with 
Pept1 (labeled or unlabeled with TAMRA), ATP7B-H1069Q rescues the 
TGN localization (Fig. 24). No such effects were observed in cells co-
transfected with CryAB-R120G (data not shown) or treated with Ctrl Pept 
(Fig.24). To further corroborate these data, we used confocal 
immunofluorescence microscopy to evaluate the colocalization of GFP and 
GOLGA2 signals with the ImageJ colocalization plugin; the obtained 
Pearson's R value is shown in the graph below (Fig. 24). These results show 
that Pept1 exerts a similar effect to full-length CryAB. 
It is in the wake of this important new evidence that we decided to look for 
a cellular model that would more closely mimic WD. First, we considered 
using human hepatocytes. However, despite remaining the gold standard 
for WD molecular analysis in the liver, their availability is very limited. 
Second, we took into consideration human hepatoma cell lines, which are 
indeed excellent cellular platforms to study ATP7B and its role in Cu 
homeostasis, as exemplified by the most widely studied hepatic cell line, 
Huh7 (Huster D. et al., 2003; Song MO. and Freedman JH. 2005). 
However, a major drawback of using this cell line is that the Huh7 and the 
other human hepatic cell lines, like HepG2 and Hep3B, express the 
endogenous, functional ATP7B, a property that can interfere with the 
localization of ATP7B-H1069Q (Lutsenko S. et al., 2007).   
Thus, in the end, we did the same experiment using the HepG2 KO hepatic 
cell line, which does not express ATP7B (data not shown) (Allocca Simona 
Ph.D thesis) and Huh7 (Fig. 25). Not surprisingly, we obtained the same 
results as those obtained in COS7 cells, thereby confirming that Pept1 
rescues the Golgi localization of ATP7B-H1069Q.  
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Figure 24. Peptide1 corrects localization of ATP7B-H1069Q from the ER to the TGN 
in COS7 cells. COS7 cells were transfected to express GFP-tagged ATP7B or ATP7B-
H1069Q and co-transfected with 3xFlag-CryAB or incubated with Pept1 and Ctrl Pept 
(12.5 µM) in the presence or absence of TAMRA for 24h post-transfection. Subsequently, 
confocal immunofluorescence analysis were performed using an anti-GOLGA2 protein 
antibody to visualize the Golgi complex. The histogram shows the extent of colocalization 
of both ATP7B and ATP7B-H1069Q with GOLGA2 (mean ± s.d., n=20 cells from 3 
independent experiments). Scale bar: 10 µm. 
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Figure 25. Peptide 1 rescues Golgi localization of ATP7B-H1069Q in Huh7 cells. Huh-
7 cells were co-transfected to express GFP-tagged ATP7B or ATP7B-H1069Q and co-
transfected with 3xFlag-CRYAB or incubated with Pept 1 and Ctrl Pept (12.5 µM) in the 
presence or absence of TAMRA for 24 hours post-transfection. Subsequentely, confocal 
immunofluorescence analyses were performed using an anti-TGN46 protein antibody to 
visualize the Golgi complex. The histogram shows the extent of colocalization of ATP7B 
and ATP7B-H1069Q with TGN46 (mean ± s.d., n=30 cells from 3 independent 
experiments). Scale bar: 10 µm. 
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4.9 The Golgi-corrected ATP7B-H1069Q moves to post-Golgi vesicles in 
response to Cu overload in the presence of Pept1 
   In previous studies, we demonstrated that Pept1 retains the ability to 
rescue the Golgi localization of ATP7B-H1069Q, as efficiently as the 
isolated crystallin domain and full-length CryAB. Encouraged by these 
findings, we decided to investigate whether Pept1 Golgi-corrected ATP7B-
H1069Q is also able to respond to copper overload.  
To address this question, we transfected COS7 cells to express GFP-tagged 
ATP7B WT or ATP7B-H1069Q. Then, after 24 hours, we incubated them 
with 12.5 µM of TAMRA-labeled or unlabeled Pept1 and Ctrl Pept. Next, 
we incubated them again for 2 hours in a medium containing either 200 µM 
of CuSO4 or 500 µM of bathocuproine disulphonate (BCS), a Cu chelator. 
Interestingly, our confocal immunofluorescence analysis using an anti-
GOLGA2 antibody (Fig. 26) revealed that Pept1, just like the full-length 
CryAB, induces the Golgi-corrected ATP7B-H1069Q to move from post-
Golgi vesicles in response to a Cu overload, similarly to ATP7B WT. 
That Pept1 facilitates ATP7B-H1069Q response to Cu overload as 
efficiently as full-length CryAB, is illustrated below in Figure 26. In 
particular, the white spots indicate a Golgi localization of ATP7B and 
ATP7B-H1069Q in the presence of Pept1 using low Cu conditions, 
whereas a dispersed punctate staining pattern of ATP7B and ATP7B-
H1069Q with Pept1 towards the cytosolic vesicular compartment is 
observed upon Cu exposure. In contrast, the Ctrl Pept does not show the 
same effect in the presence of excess Cu. The histogram (Fig. 26) shows an 
increase in ATP7B-H1069Q Golgi-localization in the presence of Pept1 
without Cu and an increase in post-Golgi vesicles after Cu treatment. 
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Figure 26. ATP7B-H1069Q responds to Cu overload in the presence of Pept1. COS7 
cells were transfected to express GFP-tagged ATP7B or ATP7B-H1069Q and incubated 
with Pept1 and Ctrl Pept (12.5 µM) for 24 hours post-transfection. Then, 2h before 
fixation, the cells were incubated with 200 µM of CuSO4 (+Cu) or 500 µM of 
bathocuproine disulphonate  BCS (-Cu). Subsequently, confocal immunofluorescence 
analysis were performed using an anti-GOLGA-2 protein antibody to visualize the Golgi 
complex. The histogram shows the percentage of ATP7B or ATP7B-H1069Q transfected 
cells exhibiting ER, Golgi complex, ER + Golgi complex and PM + vesicular staining, 
respectively (average ± s.d., n=25 cells from 2 independent experiments). Scale bar: 10 
µm. 
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4.10 Pept 1, but not Ctrl Pept, interacts with ATP7B WT and H1069Q  
 
   To evaluate whether Pept1 would interact with ATP7B WT and H1069Q, 
we performed a co-immunoprecipitation assay. Co-immunoprecipitation is 
a technique commonly used to identify protein-protein interactions. Using 
a specific antibody as a target protein, we were able to indirectly capture 
the proteins that were bound to our protein of interest. Then, we analyzed 
the co-immunoprecipitation samples using nanoLC-ESI-Q-Orbitrap 
MS/MS.  
COS7 cells were transfected to express GFP-tagged ATP7B WT or 
ATP7B-H1069Q and incubated  with Pept1 and Ctrl Pept (12.5 µM) 
labeled with TAMRA for 24 hours post-transfection. The obtained cell 
lysates were incubated first with primary antibody anti-GFP and then with 
Protein A-Sepharose beads. This protein was used because it is able to bind 
to the Fc region of the primary antibody. Proteins that are targeted by the 
antibodies are then captured onto the beads via Protein A and are easily 
recovered by low speed centrifugation. The immunoprecipitated samples 
were analyzed using nanoLC-ESI-Q-Orbitrap MS/MS by Chiara 
D'Ambrosio, a colleague working in the laboratory of Professor Scaloni at 
ISPAAM. 
Pept1 and Ctrl Pept labeled with TAMRA had the same molecular mass 
(2798.41 Da as monoisotopic value) and the same mass spectra. However, 
because they had different amino acid sequences, we were able to 
distinguish them from their different fragmentation spectra. Since both 
their mass spectra showed prominent peaks at m/z 560.69, corresponding 
to the quintuple charged ions, we monitored this value in the samples using 
the SIM mode to increase sensitivity. 
Therefore, the presence or absence of the Pept1 in immunoprecipitated 
samples from ATP7B WT and H1069Q was checked by SIM-MS 
experiment. The selected ion monitoring chromatogram clearly showed the 
occurrence of a peak at 35 min corresponding to Pept1 (Fig. 27, Panels A 
and D), as ascertained by its MS/MS spectrum (Fig. 28), only in the ATP7B 
sample containing Pept1, and WT and H1069Q. No peaks related to the 
signal at m/z 560.69 were revealed in the ATP7B samples containing 
control, WT and H1069Q, ATP7B without peptides, and WT and H1069Q 
(Fig. 27 Panels B, C, E, F).   
These results were strongly supported by FLIM analysis (data not shown) 
(Allocca Simona’s Ph.D thesis). 
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Figura 27. NanoLC-ESI-Q-Orbitrap SIM-MS analysis. Selected ion monitoring 
chromatogram (m/z 560.69 ±0.6) of ATP7B WT + Pept1 (A) ATP7B WT + Ctrl Pept (B) 
ATP7B WT (C) ATP7B-H1069Q + Pept1 (D) ATP7B + Ctrl Pept (E) ATP7B-H1069Q 
(F). Peak really corresponding to Pept1 are marked with narrows. 
 
 
Figura 28. Mass spectrum of the Pept1. Mass spectrum of Pept1 (precursor quintuple 
charged ions at m/z 560.69) from ATP7B WT + Pept1 (A) and its relative MS/MS 
spectrum (B). Mass spectrum of Pept1 from ATP7B-H1069Q + Pept1 (C) and its relative 
MS/MS spectrum (D).   
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4.11 Pept1 increases ATP7B-H1069Q half-life 
 
   Since the H1069Q mutant has a decreased half-life compared with the 
wild-type ATP7B (Dmitriev OY. et al., 2011), we asked whether Pept1 was 
also able to increase ATP7B-H1069Q half-life. To this end, HepG2 cell 
line knockout for the expression of ATP7B (HepG2 KO) were infected 
with GFP-ATP7B-H1069Q and incubated with 12.5 µM of Pept1 and Ctrl 
Pept for 24 hours. We then treated the cells with protein synthesis inhibitor 
cycloheximide (Chx) (100 µM) for 2 hours and performed Western 
blotting.  We found that when HepG2 KO cells were infected with GFP-
ATP7B-H1069Q, ATP7B-H1069Q expression level decreased after 2 
hours of Chx treatment, as well as in the presence of Ctrl Pept, whereas 
HepG2 KO cells infected with GFP-ATP7B-H1069Q and treated with 
Pept1 did not. These data demonstrate that Pept1 is able to stabilize 
ATP7B-H1069Q, thereby increasing its half-life (Fig. 29). 
 
 
     
 
Figure 29. Pept1 increases ATP7B-H1069Q half-life. HepG2 KO cells were infected 
with GFP-ATP7B-H1069Q, incubated with 12.5 µM of Pept1 and Ctrl Pept for 24 hours. 
Cells were then treated with Chx (100 µM) for 2 h and Western blotting was performed. 
Tubulin was used as loading control. The level of remaining ATP7B was quantified as the 
percentage of initial ATP7B level (0 hour of Chx treatment), as shown in the histogram. 
Data are reported as means ± SEM of two biological replicates. 
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4.12 Generation of hepatic differentiation of WD and control hiPSCs 
 
   To generate hiPSCs, in collaboration with Dr. Silvia Parisi, Anna Musto, 
Simona Allocca and Prof. Roman Polishchuk, we obtained primary 
fibroblasts from skin biopsies of a homozygous H1069Q WD patient 
(H1069Q/H1069Q) and a familiar control (WT/H1069Q). iPSCs were 
produced using an integration-free method by transfecting episomal 
plasmid vectors into primary fibroblasts (Okita K.  et al., 2011), instead of 
retro or lentivirus, thus avoiding genetic integration and the risk of 
changing the genetic asset of the patient’s cells. iPSC-like colonies 
emerged three weeks after transfection. Positivity for the stemness markers 
Nanog and Oct4 was assessed by immunofluorescence (Fig. 30).  
In WD, the liver is the most affected organ in the body, being the site in 
which Cu homeostasis occurs and in which ATP7B is primarily expressed. 
Thus, we differentiated patient and control iPSCs into HLCs using a 
previously established protocol (Si-Tayeb K. et al., 2010). This protocol 
mimics liver development by passing through three hepatic developmental 
stages: definitive endoderm, hepatic progenitors, and hepatocyte-like cells. 
We further differentiated them toward the hepatic lineage for 20 days, 
specifically until they resulted positive for hepatic cell markers such as 
albumin (ALB) (data not shown), α−fetoprotein (AFP), and α-1-antitrypsin 
(AAT) (Fig. 30). 
 
 
Figure 30. Generation of hepatic differentiation of WD and control hiPSCs. Control 
and WD patient-derived fibroblasts were reprogrammed to generate hiPSCs and then 
differentiated into HLCs. Immunofluorescence microscopy for stemness markers (Oct4 
and Nanog) and hepatic cells markers (AFP and AAT) in a representative control and WD 
clone. Nuclei are stained in blue with DAPI. Scale bars: 50 µm 
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4.13 ATP7B expression in HLCs from patient and control hiPSCs 
 
   Overexpression studies have revealed that the mutant ATP7B-H1069Q is 
subjected to rapid degradation (Payne	  AS.	  et	  al.,	  1998;	  van	  den	  Berghe	  P. 
V.	  et	  al.,	  2009;	  Chesi	  G.	  et	  al.,	  2016). It remains unclear whether isogenic 
expression of ATP7B-H1069Q equally leads to the fast turnover of the 
protein. To gain some clarifying insights, we analyzed the expression of 
ATP7B in HLCs derived from a WD patient and control iPSCs. We 
compared overall ATP7B quantities in control and patient HLCs using 
immunofluorescence assay and Western blot analysis. 
Immunofluorescence analysis revealed that the HLCs derived from patient 
iPSCs expressed lower levels of ATP7B-H1069Q compared to control 
HLCs (Fig. 31 A). Likewise, Western blot analysis detected no ATP7B 
expression in undifferentiated iPSCs from both control and patient HLCs, 
as well as from unrelated and undifferentiated human iPSCs. In contrast, 
strong expression was detected in the HLCs derived from the control iPSCs 
and unrelated human iPSCs (Fig. 31, panel B). Strikingly, the expression 
level of the mutant protein was rather low, only 30%, compared to control 
(graph in Fig. 31 B), although ATP7B mRNA levels were similar (data not 
shown). Furthermore, when HLCs obtained from control and patient iPSCs 
were incubated in the presence of the protein synthesis inhibitor 
cycloheximide, a clear reduction in ATP7B-H1069Q was observed after 4 
hours in patient HLCs. By contrast, no decrease was seen in the control 
cells (Fig. 31, panel C). Altogether, these results strongly suggest that 
endogenously expressed ATP7B-H1069Q accumulates at a steady state at 
lower levels in patient HLCs because it undergoes a faster degradation than 
the WT protein. 	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Figure 31. ATP7B expression in HLCs from patient and control iPSCs. A. 
Immunofluorescence analysis of ATP7B expression in HLCs derived from control and 
patient iPSCs.  Nuclei are stained in blue with DAPI. Scale bars: 50 µm. B. Representative 
western blotting of ATP7B accumulation at steady state in undifferentiated iPSCs and in 
differentiated HLCs. Unrelated human iPSCs were used as further control. Actin was used 
as loading control. The graph shows the relative expression of ATP7B in patient HLCs 
normalized to the level in the control HLCs. Data are reported as means ± SEM of three 
biological replicates. C. Western blot analysis of ATP7B accumulation in control and 
patient HLCs incubated for 4 hours in the absence or in the presence of 100 µM 
Cycloheximide. Actin was used as loading control. The graph shows the relative 
expression of ATP7B at the 4 hours time point normalized to the level of the 0 time point. 
Data are reported as means ± SEM of three biological replicates. 
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5. CONCLUSIONS AND DISCUSSION 
 
   This thesis has presented three main findings. The first is the 
characterization of CryAB peptide activity on H1069Q mutation of 
ATP7B, the most frequent cause of WD, in heterologous cells. The second 
is the generation of an isogenic model system derived from WD patients 
bearing H1069Q ATP7B mutation to study the properties of endogenously 
expressed ATP7B-H1069Q. The third is the dermination of the effects of 
phosphorylation on CryAB full length structure and function.  
 
 
Characterization of CryAB peptide activity 
 
   Currently, whereas about 5% of all WD patients require liver 
transplantation, less-severely affected patients can benefit from treatment 
with Cu-chelating agents and zinc. Despite being effective, these 
treatments cause serious side effects and exhibit limited efficiency in 
substantial cohorts of patients (Iorio R. et al., 2004; Beinhardt S. et al., 
2014). Thus, an alternative therapeutic approach, able to act on ATP7B-
H1069Q, the mutated protein causing the great majority of WD cases, 
would be a great therapeutic breakthrough for WD. 
 
Over the past few years, scientists have identified CryAB-derived peptides 
that mimic the chaperone activity of the full length protein (mini 
chaperones). In particular, CryAB-derived peptide corresponding to 
residues 73-92 has different functions. It acts as a mini-chaperone in vitro, 
protects human lens epithelial cells (HLE) from thermal-stress induced 
apoptosis, and inhibits selenite-induced cataracts after intraperitoneal 
injection in rats. Studies indeed suggest that mini-chaperone peptides are 
potential candidates for therapeutic use in diseases associated with protein 
aggregation. Remarkably, the beneficial results obtained in rats after 
receiving intraperitoneal adminstration of CryAB suggest that this peptide 
could be used in vivo to tackle WD (Nahomi RB. et al., 2013). 
Therefore, in the wake of these findings, we decided to investigate the mini-
chaperone activity of 73-92 peptide (Pept1) in our WD cellular model. Our 
results demonstrate that Pept1 enters the cells and does not affect cells 
viability. Most important, under overload Cu conditions, this peptide works 
as efficiently as the isolated crystallin domain and full-length CryAB in 
preventing aggregation and in rescuing ATP7B-H1069Q from the ER to 
TGN and to the post-TGN trafficking. Furthermore, Pept1 but not the Ctrl 
                                                                                     5. Conclusions and discussion 
 
   60  
Pept interacts with ATP7B WT and H1069Q, as shown by co-
immunoprecipitation assay and FLIM analysis. We also show that Pept1 is 
able to stabilize ATP7B-H1069Q, thereby increasing its half-life. Looking 
ahead, all these encouraging results will prompt us to investigate the effect 
of this CryAB peptide 73-92 on the molecular mechanisms that regulate Cu 
metabolism in WD pathogenesis. 
The use of peptides and peptidomimetics has revolutionary potential in 
therapy. However, further studies are necessary to develop strategies to 
optimize mini-chaperone peptides. Many approaches including chemical 
modifications, D–amino acid and amide bond replacements, cyclization, 
and novel amino acid substitutions could be used to stabilize and to 
guarantee better resistance and specificity (Hruby VJ. and Cai M. 2013). 
Moreover, future studies in animal models are needed to ascertain the 
toxicity and the delivery of the mini-chaperone to enable its development 
as a therapeutic agent.  
 
Generation of an isogenic ATP7B-H1069Q model system 
 
   Any potential new drug should be first validated in cellular systems 
closely resembling those of patients, then tested in animal models, and 
subsequently clinically tried on humans    as clearly shown by the deltaF-
CFTR mutant, the most common cause of cystic fibrosis (Peters KW. et al., 
2011). Similarly to ATP7B-H1069Q, the deltaF-CFTR mutant is 
extensively retained in the ER. Over the years, many screening libraries 
have identified both molecular targets and chemical compounds to 
efficiently correct CFTR (Lukacs GL. and Verkman AS. 2012). However, 
most of the correction strategies have failed to rescue CFTR function in 
patient-derived cells. The main cause of this failure is that these correction 
strategies are performed by overexpressing the mutant protein in 
heterologous cells. Thus, the ony reliable option for in vitro validation of 
novel correction disease-relevant cellular systems is to expoit the isogenic 
expression of the pathogenic mutant.  Unfortunately, any similar cellular 
system remains unavailable for ATP7B-H1069Q. Despite the rapid 
development of gene editing technologies, neither hepatic cell lines nor 
vertebrate animal models with endogenous expression of ATP7B-H1069Q 
mutant have been generated. One possible solution to tackle this problem 
would be to obtain hepatocytes from patients’ liver biopsies. However, 
owing to the scant number of cells in a biopsy and the inability of hepatic 
cells to proliferate in vitro, drug validation would be nearly impossible. For 
this reason, nowadays skin fibroblasts are being widely used to validate 
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drugs in a number of diseases    the reason being that these cells can easily 
be obtained by patients and expand in vitro (Huch M. and Koo BK, 2015). 
In this context, in collaboration with Dr. Silvia Parisi, Anna Musto, Simona 
Allocca, and Roman Polishchuk, we generated a novel cell model to study 
the H1069Q mutation of ATP7B. This model is based on the generation of 
iPSCs obtained by reprogramming primary skin fibroblasts from a 
homozygous patient and from his mother, used as control, and by 
subsequently differentiating them into HLCs. Remarkably, we found that 
endogenously expressed ATP7B-H1069Q accumulates at a lower steady 
state level in patient HLCs because it undergoes a faster degradation than 
the WT protein. 
The availability of this model has thus become paramount. Actually, 
several studies have previously reported on the generation of iPSCs from 
WD patient with R778L and M769V genetic mutations of ATP7B (Zhang 
S. et al., 2011; Yi F. et al., 2012), but not with the ATP7B-H1069Q mutant. 
Therefore, the novelty of our research lies in the generation of human 
iPSCs from a patient bearing the H1069Q-ATP7B mutation.  
Noteceably, another major advantage of our approach is that of having used 
a family member as control (the patient’s mother) as opposed to previous 
works which have used human ESCs derived from human embryo of 
unrelated individuals.  Moreover, as 40-50% of WD patients (Walshe JM, 
1962) develop neurological defects, this approach will also allow us to 
differentiate patient-derived iPSCs into neurons to better study the effect 
of H1069Q mutation on brain dysfunction.  
Thus, we are confident that this disease-relevant system with the isogenic 
expression of H1069Q mutation of ATP7B represents a novel model for in 
vitro validation of novel correction strategies in WD. 
  
Effects of phosphorylation on CryAB chaperone activity 
 
   Protein phosphorylation is the major post-translational modification in 
eukaryotic cells. This post-translational modification plays a crucial role in 
the cellular functions of proteins such as sHSP, particularly CryAB 
(Katsogiannou M. et al., 2014). Recent findings demonstrate that 
phosphorylation of CryAB at serine residues interferes with its chaperone 
activity and oligomerization. In particular, pseudo-phosphorylated CryAB-
S19D and -S45D have an inhibitory effect, either alone or in combination. 
By contrast -S59D has no such effect and counteracts the inhibition caused 
by single phosphomimetic substitutions at S19 and S45. Interestingly, all 
phosphomimetic substitutions lead to significantly decreased oligomeric 
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size of the protein, indicating that the inhibitory effect seen for S19 and S45 
cannot be ascribed to the reduction of oligomerization. 
Although several reports have investigated the effects of phosphorylation 
on the chaperone activity and oligomerization of CryAB, the results are 
controversial. For instance, recent work has demonstrated that mimicking 
phosphorylation only on Ser-59 protects cardiac myocytes against 
apoptosis by conferring maximal cytoprotection. A possible explanation to 
this phenomenon is that CryAB confers cytoprotection by interacting with 
many targets in addition to caspase-3. CryAB monomers associate with 
each other forming oligomers. The mass of the oligomers decreases in 
response to cellular stresses that, in turn, increase CryAB phosphorylation 
(Muchowski P.J. et al., 1999; Ito H. et al., 2001; Chiesi M. et al., 1990), 
suggesting that the phosphorylated CryAB monomers translocate to sites 
where they mediate cytoprotection. These results also imply that CryAB 
monomers serve as efficient chaperones (Morrison LE. et al., 2015). In 
glioma cells, using centrifugation on a sucrose density gradient, researchers 
show that pseudophosphorylation at the serine residues 19, 45, 59 
determines the formation of small oligomers associated with a reduced 
chaperone activity (Ito H. et al., 2001). By contrast R120G mutation, which 
is known to cause desmin-related cardiomyopathy, forms great oligomers 
(over 645 kDa); yet, this form is defective in chaperone activity (Bova MP. 
et al., 1999). Thus, phosphorylation status, CryAB oligomerization state, 
and chaperone activity have no direct and simple relationships. Most likely, 
CryAb is endowed with a fine regulatory system that recognizes different 
client proteins where phosphorylation plays an important role in controlling 
this activity. Ths line of research clearly warrants further investigation. 
Regarding a possible explanation for how phosphorylation controls CryAB 
chaperone activity, studies show that CryAB uses its intrinsic structural 
plasticity to expose distinct binding interfaces and thus interacts with a 
wide range of structurally variable clients (Mainz A. et al., 2015). This 
observation led us to speculate that phosphorylation plays an important role 
in controlling CryAB conformation state and plasticity. Consequently, any 
change in phosphorylation patterns may differently interfere with CryAB 
chaperone function. For instance, studies show that the phosphorylation 
pattern that inhibits chaperone activity of CryAB for FZ4-FEVR and 
ATP7B-H1069Q (S19D, S45D, S19 /45D or 3D) better protects k-casein 
but not the formation of amyloid fibers ccß-Trp peptide (Ecroyd H. et al., 
2007). Thus, CryAB phosphorylation has a different effect depending on 
the aggregation prone protein engaged.  
It has been recently reported that MAPK signaling pathways have a crucial 
role in the response to endoplasmic reticulum stress and unfolded protein 
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response (UPR) (Darling N.J. et al., 2014). In particular, the MAPK 
signaling pathway is essential in regulating many cellular processes 
including cell cycle progression, cell survival, apoptosis, inflammation, 
cell stress response, and cell differentiation. (Pimienta G. and Pascual J., 
2007; Raman M. et al., 2007; Shaul Y.D. et al., 2007). Among 
conventional MAPKs (ERK1/2, JNK and p38), ERK1/2 and p38 seem to 
have a fundamental role in the regulation of several HSPs including CryAB 
(Robitaille H. et al., 2010; Mitra A. et al., 2014; Zhu Z. et al., 2015). In 
particular, whereas S45 (and possibly S19) is phosphorylated by ERK1/2, 
S59 is phosphorylated by p38-dependent MAPK (Kato K. et al., 1998). 
Most important, p38 MAPK down-regulates ERK1/2 (Lu Z. et al., 2006), 
suggesting that in the cell, phosphorylation on serine residue 59 may be 
followed by a negative regulation of the phosphorylation at serine residues 
19 and 45. Thus, the protective role of phosphomimetic S59 when CryAB 
is also pseudophosphorylated on serine 19 or 45 is accompanied by the 
negative regulation of ERK1/2 by p38 MAPK. Interestingly, recent 
findings have shown that ATP7B-H1069Q overexpression in HepG2 cells 
activates p38 MAPK, which, in turn, favors its retention in the ER and   
rapid degradation. By contrast, suppression of this pathway by p38 
inhibitors results in substantial rescue of ATP7B-H1069Q from the ER to 
TGN compartment (Chesi G. et al., 2016). However, as CryAB is 
expressed at very low levels in hepatocytes and hepatoma cell lines, these 
observations should be verified in cell expressing significant amount of the 
chaperone.  
Conversely, p38 kinase activity is required for the phosphorylation- 
dependent nuclear translocation of the spliced form of the X-box binding 
protein 1 (Xbp1s).  Perturbations of ER homeostasis can create an ER stress 
and determine the activation of a group of complex signaling pathways 
known as unfolded protein response (UPR). Xbp1s is produced during 
UPR, which normally occurs when unfolded proteins accumulate in the ER. 
(Lee J. et al., 2011). Since TMPs exhibit domains on both the luminal and 
the cytosolic side of the ER, mutations affecting their folding and export 
from the ER most likely require the coordinated activation of chaperones 
acting from both sides of the ER membrane. Accordingly, the MAPK 
signaling pathway could provide this coordination by participating in UPR 
both to generate the response in the lumen and, simultaneously to protect 
CryAB cytosolic chaperone activity to assist TMPs (Ciano M. et al., 2016).
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